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Abstract
The isolation and identification of effective antiviral
compounds that do not harm host cell activity is difficult.
Small changes in functional groups or molecular conformation
of a compound can dramatically affect its virucidal activity
and cytotoxicity. Greater complexity is encountered in in-
vivo biological systems than in in-vitro model test systems.
This research has examined the virucidal activity of
amphipathic compounds upon the lipid-enveloped phage ~6 and
the protein-coated, lipid-containing phage PM2.
Glycyrrhizin and seven selected retinoids, all amphipathic
compounds, were investigated to determine their virucidal
activity.
In this research, the results of plaque assay
experiments of glycyrrhizin on phage ~6 showed a 98%
inactivation at concentrations as low as 1.0~M and up to
100% inactivation at concentrations at or above 10.0~M with
no host cell cytotoxicity at concentrations as high as 10mM.
Glycyrrhizin showed virucidal effects against the protein-
coated phage PM2 but these results were less effective when
compared to the inactivation results upon the external
lipid-enveloped phage ~6.
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To characterize the effects of in-vivo complexities,
two factors were examined. Previous work in this lab has
shown that temperature and fatty acids could effect the
activity of a virucidal compound. In this study, each of
these were seperately examined and modified within the in-
vitro phage ~6 test system. In this study, incubation
temperature was varied and the effect upon the virucidal
activity of glycyrrhizin was determined. Unexpectedly,
temperature had no appreciable effect on the virucidal
activity of glycyrrhizin. Also in this study, individual
exogenous lipids were added prior to incubation with
glycyrrhizin. Some of the lipids tested; such as
arachidylic acid, phosphatidyl choline and cholesterol; are
capable of providing a substantial protective effect at
ratios as low as 1:100 (lipid: glycyrrhizin) against the
virucidal activity of glycyrrhizin. other exogenous lipids
tested; such as stearic acid, oleic acid, and caprylic acid;
did not show any interference with the virucidal activity of
glycyrrhizin.
Previous work in this lab has shown that the all-trans
isomers of retinal, retinol and retinoic acid have virucidal
effects. Retinoic acid (all-trans) showed the greatest and
substantial virucidal activity against the phage PM2.
Retinal and retinol showed the greatest virucidal activity
against phage ~6. Recently a number of cis-isomers of these
2
same retinoids became available and in this research their
virucidal activity was studied and compared to their
corresponding all-trans isomer results on the phage PM2. In
this research, the 13-cis-isomer of retinoic acid showed an
appreciably lower inactivation of the protein-coated phage
PM2 compared to the all-trans isomer of retinoic acid. The
structural kink in the cis-isomer may reduce the ability of
the polar tail to intercalate into the protein coat. In
this research, the eOOH R group of retinoic acid was the
most virucidal retinoid against PM2 among the retinoids
tested. Other cis-isomers did not show any increase or
overall change in virucidal activity compared to their all-
trans isomers against PM2.
The results of this study have added to the
appreciation for the complications arising from in-vivo
system variables, variations in the degree of virucidal
activity due to changes in isomeric configurations, and
effects of different functional groups against different
external viral surfaces. Collectively, these observations
can add to the overall understanding needed for the
prediction, selection, and design of effective antiviral
compounds.
3
Introduction
1. Background Material
~ Antiviral Agents
Antiviral agents can act and are therefore classified
in several different ways (13, 14, 15). Antiviral or
chemotherapeutic compounds can act directly upon a virus
particle outside of a host-cell and are termed virucidal
agents. Chemotherapeutic compounds that interfere with
stages of a viral life cycle such as viral attachment,
production, assembly or release are termed virostatic
compounds (13). Chemotherapeutic compounds that enhance or
aid in the immune system's detection and clearance of a
viral presence or infection are called immune adjuvants
(17) . Subcomponents of a virus particle that solicit a
protective level of immune system antibodies are termed
vaccines. Current immunization research also includes
missense mutations in viral genes, gene incompatabiliy and
live attenuated virus technologies (16).
Chemotherapeutic compounds clinically in use today act
as virostatic compounds. Current antiviral drugs in
clinical use include acyclovir, amantadine and AZT (14, 15).
AZT and acyclovir are semi-synthetic nucleotide analogues.
While these compounds, at clinical doses, have only mild
side- effects they are not 100% effective and do not provide
complete clearance of the viral infection (15). More
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research is still needed to identify additional antiviral
alternatives. While vaccine technology is dramatically
advancing, many virus infections do not lend themselves to
being prevented by vaccines due to rapid and diverse viral
mutations or the inability to target an effective antigenic
subcomponent of the virus (16).
It is reasonable to believe that other untested and
effective chemotherapeutic agents exist and that the
investigation for such compounds is a worthwhile endeavor.
There are many sources for chemotherapeutic antiviral agents
which include plant sources, animal sources, insect sources,
novel microorganism protein and enzyme compounds, organic
derivatives or synthetic compounds (14).
Plant sources have long been and still are a major
source for numerous classes of pharmaceutical agents (8).
Part of the research described in this thesis has focused on
a plant source for a novel, specific and identified compound
called glycyrrhizin obtained from the Chinese Licorice Plant
Root. In addition, the research described here has also
examined organic retinoid compounds and several semi-
synthetic isomer derivatives.
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~ Lipid-containing Bacteriophages
The discovery and characteristics of lipid-containing
bacteriphages began in 1968 with the isolation of PM2 (5)
which infects Alteromonas espejiana, a marine bacterium
previously termed BAL31 (Pseudomonas) (6). Another lipid-
containing bacteriophage, ~6, which infects Pseudomonas
phaseolicola, was discovered in 1973 by Vidaver et. al. (7).
The lipid-containing bacteriophages ~6 and PM2 share
some comparative structural characteristics with a few human
pathogenic lipid-containing viruses such as herpes simplex
virus, influenza, and poxviruses. In addition, PM2 shares
some comparative characteristics to protein-coated viruses
such as SV40.
The lipid membranes of ~6 and PM2 are composed of
phospholipids that form a bi-layer around the virus to form
an envelope. The phospholipids are obtained from the host
cell (6) . The envelope depicted by hashed region is
external in the case of ~6 and internal for PM2 as
depicted in Diagram 1 below. The envelopes have associated
proteins which participate as important mechanisms in phage
attachment and penetration. The fatty acid composition of
each virion is similar to its host cell (2).
cells can be grown at room temperature.
6
Both host
Diagram 1: Schematic of Bacteriopahges ~6 and PM2
~6 PM2
The following table summarizes some of the general
properties of PM2 and ~6 bacteriophages depicted in this
diagram.
Phage Genome structure proteins Lipid
~6
PM2
dsRNA Icosahedral 10
M.W. lOE6 core diam 60nm
total 75nm
dsDNA Icosahedral 4
circular 60nm diam
M.W. 6E6
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External
Phosphatidyl-
glycerol rich
Internal
Phosphatidyl-
glycerol rich
Bacteriophage PM2 is 60nm in diameter and contains 12%
lipid which is found in its internal lipid membrane. The
lipid composition of PM2 is 64% phosphatidylglycerol, 27%
phosphatidylethanolamine, 7% neutral lipid and 1% acyl-
phosphatidylglycerol. The lipid is obtained from the host
bacteria Alteromonas espejiana (previously identified as
BAL31). BAL31 is a gram-negative marine bacterium and its
lipid composition is 75% PE and 23% PG. Phage PM2 lipid
composition ratio is not a reflection of the host. Phage
PM2's fatty acid composition is similar to its BAL31 host.
Phage PM2 is 56.6% C16 : 1 ' 12% C16 : O' 13.9% C18 : 1 and 7.3%
C17 : cy a cysteine sulfoxyl linked fatty acid. 62% of phage
PM2 volume is H20 and 42% of the H20 is contained in the
viral core.
Phage PM2 contains circular double stranded DNA of a
molecular weight of 6 x 106 . The virion contains four
proteins. Two of the virion proteins, I and II, are
external. Protein I surrounds the virion lipid membrane and
protein II protrudes and extends outside the protein coat of
protein I. Two proteins, III and IV, are internal to the
lipid membrane in the virion core.
Inactivation experiments using the retinoid, retinoic
acid, on PM2 have demonstrated that the acid COOH (COO-)
group at the end of the polar tail is the most active
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functional group. It is postulated that this functional
group interacts with the protein coat and possibly down into
the internal lipid bilayer causing virion particle
disruption (1, 4).
The adsorption rate of phage PM2 is 3.4 x 10-9 m/min.
Synthesis of host DNA stops early in infection but synthesis
of viral mRNA stably continues throughout infection. The
latent period is about 40-45 minutes. Mature virion
particles emerge 36 minutes after infection.
Bacteriophage ~6 host cell is a prototrophic
phytopathogen or a bean plant pathogen, Pseudomonas
phaseolicola, previously identified as HB10Y. Phage ~6
attaches to host pili. The exact structure of all
components of ~6 are not well characterized.
Bacteriophage ~6 contains 3 segments of double stranded
RNA of 2.3 x 106 MW, 3.1X106 MW, and 5.0 x 10 6 M.W.. The
exterior lipid bilayer structure of the virion is amorphous
containing lipid, fatty acid and protein and is 60-70 nm in
diameter. The core capsid is icosohedral an measures about
50nm in diameter. The inner DNA containing region comprises
a volume diameter of about 30nm and composes 12% of the
virion.
Bacteriophage ~6 is about 25% lipid. Of the 25% lipid
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composition of ~6, 57% is PG, 35% is PE and 8% is
cardiolipin (diPG) and acylPG. In the host cell, unlike
~6, the PE is present in quantities twice that of PG. The
fatty acid composition of phage ~6 is similar to the host.
About 61% of the fatty acid composition of ~6 are
saturated composed of C16 : 1 and C18 : 1 . About 33% of the
fatty acid composition of
C16 : O•
~6 are unsaturated composed of
Bacteriophage ~6 codes for 11 known proteins.
Proteins P1 and P2 are involved in RNA polymerases
activities and constitute 15.6% and 6% of the total protein
composition. Protein P3 is the lipid envelope surface
attachment protein and comprises 9.8% of the total protein
composition. Protein P6 (2%) is also part of the surface
attachment protein on the lipid envelope. Protein P8,
26.3%, is used in the structure of the nucleocapsid.
Proteins P5 (3%), P9 (18%), P10 (9.5%) and P11 (6%) are part
of the amorphous lipid bilayer and interact with the
nucleocapsid. Protein P12 is a non-structural protein used
in assembly of the envelope. (2,7).
Inactivation of phage ~6 has been most effective with
the retinoids, retinal and retinol. The functional R group
at the end of the polar tail interacts with the lipid
bilayer causing the release of the attachment protein P3
10
from the virion envelope without major particle disruption
(1,4).
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~ Glycyrrhizin ( a triterpene )
Pharmaceutical compounds have long been isolated from
plant sources and are known as phytopharmaceuticals. A
number of unexplored plants and the novel compounds they
contain may hold promise for treatment or cure of some viral
diseases.
About 80% of modern medicines have evolved from herbal
or plant medicines (9). Some modern medicines like aspirin,
salicylic acid, continue to be the same active component of
the original plant extract. The plant, glycyrrhiza
leguminosae, has been used in herbal medicine
years. The plant root contains novel triterpene molecules
in glycoside compounds known as glycyrrhetic acid along with
several other related aglycones (10, 11).
Glycyrrhizin or glycyrrhetic acid is a known anti-
herpetic compound (8, 12). The compound was shown to be
both virucidal and also to interfere with virus replication
in cell culture. In addition to HSV-1; VSV, vaccinia, and
Newcastle disease virus were all sUbstantially inhibited by
glycyrrhizin. These four membrane-containing viruses were
inhibited 2 to 3 logloPfu in Hep-2 cells by 8mM glycyrrhizin
both immediatly after infection and almost as well at 3 hpi.
At this concentration there was no cell cytotoxicity (12).
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Glycyrrhizin has been tested, as described in this
thesis research, chiefly on the bacteriophage ~6 for any
virucidal activity. The outer lipid membrane structure of
~6 is grossly similar to that of HSV.
USV
12.0-30001\1 J,t2...
Diagram 2
comparison of ~6 and HSV outer envelope structure
The results that have been obtained on the virucidal
activity of glycyrrhizin on ~6 from this research can be
compared with the reported results on herpes virus. The
interest in testing a potential_antiviral compound is not
only to determine if antiviral properties exist but also at
what concentrations they occur. Additional considerations
include whether or not the compound is host-cell cytotoxic
at effective antiviral concentrations and what additional
factors increase or decrease the antiviral activity of a
compound.
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Diagram 3. structure of Glycyrrhetic Acid ( Glycyrrhizin)
HO
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~ Retinoids
A number of trans-isomer retinoid compounds were
previously tested in earlier experimental work to determine
their virucidal activities on both PM2 and ~6 phages (1,
4) . Synthetic retinoids in the cis-isomer conformation
were not available at that time.
Retinoic acid was shown to be the most active of the
retinoid compounds tested on PM2 with inactivation occuring
at 6~M. PM2, whose lipid bilayer is internal surrounded by
a protein coat, also showed inactivation by retinal and
retinol at concentrations above 175~M but was much less
susceptable to the retinol and retinal compounds than ~6.
The mechanisms for inactivation of PM2 are not exactly known
but are believed to be caused by particle disruption.
Retinol and retinal (all trans) have been shown to be
potent inactivators of ~6 to greater than 99% inactivation
at 0.35~M concentrations within 30 minutes. Phage ~6
showed a degree of inactivation by retinoic acid but was
less susceptable than PM2. The mechanism of inactivation
for ~6 has been shown to be facilitated by the release of an
external envelope protein P3 (3, 4). P3 is an attachment
protein required for infection. The release of P3 does not
cause substantial virus particle disruption (3,4).
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Previous work in this lab had determined the percent
inactivation curves of several compounds on phages ~6 and
PM2 and also on the human virus HSV-2 (1). Those results
are summarized here. Fifty percent inactivation was
achieved by retinol upon ~6 at a concentration of O.l~M.
Retinol (all-trans), retinal (all-trans), and retinyl
acetate achieved 100% inactivation of phage ~6 by 0.4~M
concentrations of each. Retinoic acid (all-trans) achieved
50% inactivation of ~6 at a concentration of 0.8~M and 100%
inactivation at 11.0~M concentration. To achieve 50%
inactivation of PM2, greater than 175~M concentrations of
retinal (all-trans), retinol (all-trans), retinyl acetate
were required. To acheive 50% inactivation of phage PM2 by
retinoic acid a concentration of 6~M was required. To
achieve 50% inactivation of HSV-2i 0.45~M concentration for
retinal (all-trans), 10.0~M concentration for retinol (all-
trans), and 33~M concentration for retinoic acid were
required. Inactivation experiments upon phage ~6, phage PM2
and human herpes virus HSV-2 were performed by incubating 5
x 105 PFU/ml of phage at 20°C, for 30 minutes and with each
respective retinoid concentration.
Several all-trans isomers of the retinoids have been
shown to have virucidal effects on PM2, especially retinoic
acid. In recent years four cis-isomers of these retinoids
have become available. One objective of this research is to
16
determine the virucidal activity of the four cis-isomers
upon phage PM2 and compare the virucidal effectiveness of
the cis-isomers to the all-trans isomers.
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Shown below are the compounds that were tested for
virucidal activity on the PM2 phage in the present study.
Diagram .L. Retinoid structures
Retinal Isomers
Retinal (all trans)
9-cis-Retinal
13 -cis-Retinal
Retinol Isomers
Retinol (all trans)
I3-cis-Retinol
Retinoic Acid Isomers
HeRetinoic acid (all trans) J
I3-cis-Retinoic Acid
18
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2. Overall Rationale and Research Aim
It is important to determine if a compound 'shows
antiviral activity but more to determine importantly at what
concentration does the antiviral activity occur. In
addition, it is important to determine and identify what
other factors contribute toward or interfere with the
antiviral activity of a compound. This research has
examined single, controlled factors which affect the
virucidal activity of a compound and what kind of
generalizations can be proposed for predicting and selecting
antiviral agents. In part of this research, two simple
variables were individually introduced and their effects on
antiviral activity were observed. Both temperature range
and the presence of exogenous lipid compounds were
individually introduced into an antiviral testing system.
Experiments to observe the effects of temperature and
exogenous lipids on the virucidal activity of glycyrrhizin
were performed. In addition this research has examined two
kinds of external viral surfaces and their susceptibleness
to amphipathic compounds. A new amphipathic compound was
tested on a lipid enveloped phage. Synthetic isomers of
retinoids were examined and their virucidal results were
compared to their all-trans isomers in order to further
elucidate mechanisms of amphipathic retinoid compound
inactivation of a protein-coated phage.
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Experimental data were collected using the plaque-assay
method and the following subsequently determined:
* the degree of virucidal activity of a known anti-
herpetic compound glycyrrhizin on ~6 compared to PM2
* the effects of temperature on the virucidal activities
of the antiviral compound glycyrrhizin
*
*
*
*
the ability of select exogenous lipids to act as a
neutralizing agent against the virucidal activities of
the virucidal compound glycyrrhizin
the degree or lack of recovery of the virucidal
activity of glycyrrhizin in the presence of protective
levels of a lipid neutralizing agent
how the cis retinoid isomers compare with the all-trans
isomer's virucidal activity on the phage PM2
which retinoid functional groups show greater virucidal
activity on protein-coated phages compared to those
functional groups more active on lipid-enveloped
phages; including comparisons of their cis isomers
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III. Glycyrrhizin and ~6 Studies
1. Glycyrrhizin antiviral activity upon ~6
~ Rationale and Hypothesis
Since glycyrrhizin has been reported effective as a
virucidal agent against HSV and both ~6 and HSV are lipid
envelope viruses, I believe that glycyrrhizin is acting on
some lipid and protein components on the lipid-envelope of
HSV. Phage ~6 has an attachment protein P3 within its lipid
membrane. Lipid envelopes, while composed mostly of lipid,
are usually amorphous and contain varying amounts of protein
components. Virucidal compounds inactivating ~6, such as
retinol and retinal did so by causing release of with the P3
protein from the lipid membrane (1, 4). I had hypothesized
that glycyrrhizin would also be an effective virucidal agent
against phage ~6. The inactivation of ~6 may suggest that
. glycyrrhizin might be interacting with lipid and protein
within the viral envelope of ~6 and perhaps other lipid
envelope viruses such as HSV. Glycyrrhizin is, like other
virucidal compounds, believed to be dislodging the P3
attachment protein. I had also hypothesized that the
virucidal activity of glycyrrhizin would be more vigorous
upon an external lipid membrane rather than an external
protein coat. In this research glycyrrhizin has also been
tested on PM2, a protein coated phage. I had hypothesized
that glycyrrhizin would be less effective on PM2 than ~6,
due to the lack of an external lipid envelope on PM2.
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~ Experimental Design and Method
The general plaque assay method was followed. Tubes
containing 5 x 105 PFU/ml of phage ~6 were prepared at a
volume of 10ml. Respective concentrations of glycyrrhizin,
listed below, were added at time t=o and vortexed. All
tUbes incubated for 30 minutes. Final plating
concentrations of 5 x 103 PFU/ml and 5 x 101 PFu/ml of the
above tUbes were made by dilution. A volume of O.lml of
tubes
the
were
agar
which
phage concentration samples were added to 10ml top
tUbes which already contained 0.4ml of bacterial host
was then vortexed and immediatly plated. Top agar
were cooled to below 45°C before either host or phage
added. Immediatly after host and phage were added to
cooling top agar, the incubation tUbes were vortexed and
then plated. Plates sat for 24-36 hours and then plaques
were counted.
Several concentrations of glycyrrhizin were used,
namely, O.O~M, O.l~M, 1.0~M, 10.0~M, 100.0~M. These
concentrations were all soluble in V-Medium (see Appendix A)
which was used for host cell growth. The O.O~M
concentration of glycyrrhizin acted as a control and to
anyieldednormalize percent inactivation. This
inactivation curve for glycyrrhizin on ~6.
In addition, experiments were done to test the effects
of glycyrrhizin on normal host lawn growth without any phage
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present. This was performed to ensure that plaque counts
and host lawn morphology is soley due to phage inactivation
and not from interference of the glycyrrhizin with normal
host growth.
The exact same experimental method was also performed
using phage PM2, its respective host and medium, in place of
phage ~6.
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~ Data section
TABLE 1. Plaque Count Data obtained from Inactivation
Studies of Glycyrrhizin upon the bacteriophage ~6.
PLAQUE COUNT PER PLATE
Plated Concentration of Phage ~6
Incubation 5 x 103 PFU/m1 5 x 101 PFU/m1 Average
Concentration Percent
of Experimental Runs Inactivation
Glycyrrhizin #1 #2 #3 #4 #1 #2 #3 #4
0.0 JJM »> »> »> »> 69 57 90 61 0%
0.1 JJM 720 620 » » 9 7 9 6 88%
1.0 JJM 480 310 440 471 4 3 4 3 98.5%
10.0 JJM 3 1 3 1 a a a a 99.9%
100.0 JJM a a a a a a a a 100%
The above data was obtained using the plaque assay
at an incubation time of 30 minutes, incubation temperature
of 20°C, and a phage ~6 incubation concentration of 5X105
PFU/ml.
Th~re were two plated concentrations of phage ~6
namely, 5xlO PFU/ml and 5xlO PFU/ml with host HB10Y. The
experiment was run four times at five concentrations of
glycyrrhizin. A count of plaques per plate were made. An
average of percent inactivation was calculated from an
average of plaque count data from each plated concentration,
across all four runs, and a percentage was then based on
O.O~M control at 0% inactivation.
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Qualitative Effect 1
Test of Glycyrrhizin on Normal ~6 Host (HB10Y) Lawn Growth
A concentration of lOO~M of glycyrrhizin was added to
the top agar of several plates along with host bacteria
HB10Y without phage. At the same time, control plates were
also prepared with only host bacteria HB10Y and no
glycyrrhizin or phage. A comparison of results showed no
effect, adverse or otherwise, in normal HB10Y bacterial
lawn growth, thus demonstrating that the antiviral activity
of glycyrrhizin is not interfering with normal host growth
of HB10Y at concentrations well above those that occur after
incubation dilutions. Plaque morphology or plaque reduction
can be grossly attributed to viral inactivation during
incubation.
25
ncomparative Inactivation study on Phage PM2
TABLE 2. Plaque Count Data obtained from Inactivation
Studies of Glycyrrhizin upon the bacteriophage PM2.
PLAQUE COUNT PER PLATE
Plated Concentration of Phage PM2
Incubation 5x103 PFU/ml 5x101 PFU/ml Average
Concentration Percent
of Experimental Runs Inactivatio
Glycyrrhizin #1 #2 #1 #2
0.0 pM »> »> 58 62 0%
0.1 pM »> »> 77 66 -19%
1.0 pM »> »> 65 59 -3%
10.0 pM » » 41 51 23.3%
100.0 pM 410 480 40 49 25.0%
The above data was obtained using the plaque assay at
an incubation time of 30 minutes, incubation temperature o~
20°C, and a phage PM2 incubation concentration of 5xlO
PFU/ml.
There were two plated concentrations of phage PM2
namely, 5xl03 PFU/ml and 5xl01 PFU/ml with host BAL31. The
experiment was run two times at five concentrations of
glycyrrhizin. A count of plaques per plate were made. An
average of percent inactivation was calculated from an
average of plaque count data from each plated concentration,
and both runs, and a percentage was then based on O.O~M
control at 0% inactivation.
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Qualitative Effect 2
Test of Glycyrrhizin on Normal PM2 Host (BAL31) Lawn Growth
A concentration of 100~M of glycyrrhizin was added to
the top agar of several plates along with host bacteria
BAL31 without phage. At the same time, control plates were
also prepared with only host bacteria BAL31 and no
glycyrrhizin or phage. A comparison of results showed no
effect, adverse or otherwise, in normal (BAL31) bacterial
lawn growth, thus demonstrating that the antiviral activity
of glycyrrhizin is not interfering with normal host growth
of BAL31 at concentrations well above those that occur after
incubation dilutions. Plaque morphology or plaque reduction
can be grossly attributed to viral inactivation during
incubation.
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~ Graph section
GRAPH 1. Percent Inactivation Curve for Glycyrrhizin on ~6.
Percent Inactivation Curve
Glycyrrhizin on Phl6
120..------------------------------,
100.0 uM10.0uM1.0uM0.1 uM0.01 uM
.......................................-- ..- -.::~---------.100
110
gO
c
a 80
.j;:;
lt1
> 70p
0
lt1 60l;
....
C 50Q)
0
"- 40Q)
0..
30
20
10
0
Concentration of Glycyrrhizin
The above inactivation curve was obtained from data using the
plaque assay at an incubation time of 30 minutes, incubation temperature
of 20°C, and a phage ~6 incubation concentration of SxlOS PFU/ml and at
five concentrations of the compound glycyrrhizin.
There were two plated concentrations of phage ~6 namely, Sxl03
PFU/ml and Sxl01 PFU/ml with host HB10Y. The experiment was run four
times at five concentrations of glycyrrhizin. A count of plaques per
plate were made. An average of percent inactivation was calculated from
an average of plaque count data from each plated concentration, across
all four runs, and a percentage was then based on the O.OpM control
value of 0% inactivation. A percent inactivation was determined for
all five concentrations of glycyrrhizin.
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~ Results Summary
The results indicate a very effective virucidal
activity of glycyrrhizin upon phage ~6. Virucidal
activity begins at concentrations as low as O.l~M of
glycyrrhizin yielding a 88% inactivation. A 98.5%
inactivation of ~6 was seen at 1.0~M glycyrrhizin. There
is further inactivation, up to 100%, at higher
concentrations but for all practical purposes complete
inactivation of ~6 occurs at a 10.0~M concentration of
glycyrrhizin with an actual inactivation of 99.9%. The
result of the test involving the presence of only
glycyrrhizin (no phage) on normal growth of ~6 host (
HB10Y) lawn growth showed no effect, adverse or otherwise.
TABLE 3. Percent Inactivation by Glycyrrhizin upon ~6
compared to Percent Inactivation upon PM2.
PERCENT INACTIVATION COMPARISON
Percent Inactivation
Incubation
Concentration
of
Glycyrrhizin
0.0 ~M
0.1 ~M
1.0 ~M
10.0 ~M
100.0 ~M
Phage PM2
0.0%
- 19.0%
3.0%
23.3%
25.0%
Phage ~6
0.0%
88.0%
98.5%
99.9%
100.0%
Table 3
namely, PM2
glycyrrhizin.
3.
shows the percent inactivation for each phage
and ~6, at each respective concentration of
These data were taken from Table 2 and Table
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Results of glycyrrhizin virucidal activity on PM2 show
that at concentrations of O.l~M and 1.0~M there is an
anomalous increase in plaque formation. At concentrations of
10~M and 100~M of glycyrrhizin a 24% inactivation of phage
PM2 occurs. The percent inactivation of PM2 at respective
concentrations of glycyrrhizin is comparatively less than
for those of phage ~6 inactivation results.
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~ Conclusions and Discussion
The objective of this part of the research was to test
the virucidal activity of a reported phytopharmaceutical
antiviral agent, glycyrrhizin, on two different phage-host
systems. Two phage types, comparatively different in
structure, where examined. The hypothesis was that the
lipid-envelope phage ~6 would be suscept~ble to the
virucidal activity of glycyrrhizin. In addition the
hypothesis included that the lipid enveloped phage ~6 would
be more susceptible to the virucidal activity of
glycyrrhizin than the protein-coated phage PM2 would be. In
addition there was an important interest in examining just
how potent of a virucidal agent glycyrrhizin was on each
phage ( ~6 & PM2). Virucidal results from glycyrrhizin on
each phage PM2 and ~6 were to be compared and correlated to:
the reported work of glycyrrhizin against HSV and
the similar work of retinoids against ~6 and PM2.
Finally, as with any virucidal agent, it was essential
to verify that the antiviral activity being observed was
virucidal and not cytotoxic to the host. Control
experiments were performed and did show that glycyrrhizin
did not interfere with normal growth of either host.
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As seen from the results in Table 1, glycyrrhizin is a
potent virucidal agent against ~6 phage. The ~6
envelope structure is composed of mostly lipids and some
protein receptors as previously described in the
introduction. The activity of glycyrrhizin is virucidal
and in this research does act upon both phages tested, ~6
and PM2, and does not interfere with normal growth of either
host. As seen from Data Table 2, glycyrrhizin is not as
potent of a virucidal agent against the protein-coat phage,
PM2i at least when compared to the inactivation results
against the lipid-enveloped ~6. Glycyrrhizin is virucidal
to PM2, but at higher concentrations. Most other potent
virucidal agents acting on phage ~6, such as retinal and
retinol, (1) have been consistently shown to act by
dislodging a susceptible envelope protein. I also believe
glycyrrhizin may be acting upon this envelope protein. A
more important observation is that the overall exterior
structure of the virus may need to be comprised mostly of a
lipid composition, such as with ~6 and HSV. If such is
the case, it is an important factor in the intelligent
design or selection of virucidal compounds. This is further
substantiated because the protein outer-structure of PM2 is
not as susceptible to virucidal activity of the amphipathic
compounds glycyrrhizin and retinal.
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When comparing glycyrrhizin and retinal, in addition to
their amphipathic structure, the CHO functional group is the
most active functional group, in each of their respective
polar regions. Perhaps a consistent requirement for this
active functional component of these virucidal molecules is
an interaction with a lipid membrane that is external and
mostly lipid which containing at least some susceptible
functional proteins.
One objective was to determine the inactivation curve
for the virucidal activiy of glycyrrhizin upon ~6. Another
objective was to look for a correlation between inactivation
results of HSV compared to inactivation results of ~6 when
glycyrrhizin and retinoids were each tested upon both
viruses. Glycyrrhizin has been shown (8) to have
appreciable antiviral activity (50% phage reduction) against
herpes simplex virus (HSV) at concentrations of about 200~M.
The positive correlation between the virucidal effects of
glycyrrhizin upon both lipid-enveloped viruses ~6, HSV and a
few other lipid-containing virus further substantiates the
use of phage ~6 as an early experimental system for testing
potential virucidal agents targeted against lipid-enveloped
viruses. The following table takes results from this
research and results from both previous and reported data
and makes a comparison between retinoid activity upon phage
~6 and HSVi and glycyrrhizin activity upon ~6 and HSV.
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Table 4. Comparison between Required Concentrations of
Glycyrrhizin and several Retinoids upon both
the human virus HSV and the bacteriophage ~6
at which 50% Inactivation of Virus is Achieved.
COMPARISON OF THE VIRUCIDAL CONCENTRATION REQUIRED
FOR 50% INACTIVATION OF VIRUS
Table 4 displays results from this research and results
from both previous and reported data and makes a comparison
between retinoid activity upon ~6 and HSVi and glycyrrhizin
activity upon ~6 and HSV. The comparison indicates the
concentration of each compound required to achieve 50%
inactivation of virus.
The collective comparison of the above results does
suggest a positive correlation between the virucidal effects
of glycyrrhizin and retinoids upon both lipid-enveloped
phage ~6 and the human virus HSV and does further
substantiate the use of phage ~6 as an early experimental
system for testing potential virucidal agents targeted
against lipid-enveloped viruses.
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2. Temperature effects upon The Virucidal Activity of
Glycyrrhizin upon ~6
~ Rationale and Hypothesis
In an in-vivo system the activity of a potential
antiviral compound becomes more complicated. In an attempt
to be able to measure and control individual and independent
variables and yet only add one degree of complexity, the
plaque assay method was utilized with a known virucidal
compound, glycyrrhizin, upon the phage ~6 with a temperature
variable during incubation with the phage and various
concentrations of glycyrrhizin.
Changes in temperature affect both the phage and the
antiviral compound during incubation. The objective of this
part of the research was to see what and how much of an
effect changes in incubation temperature would have on the
virucidal activity of glycyrrhizin against phage ~6. The
activities of molecules and the structure of viral membranes
may alter the virucidal potential of an antiviral compound.
These effects of temperature could be due to structural
changes in molecules or simply by changes in physical
interactions involved between the viral lipid membrane and
glycyrrhizin.
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I had hypothesized that in addition to viral lipid
membrane reactions to temperature that larger or more
complex antiviral molecules, such as glycyrrhizin, would
have shown some appreciable degree of change in their
virucidal effectiveness due to variations in incubation
temperature.
Initial inactivation experiments were performed at room
temperature. In this part of this research ranges in
incubation temperature above and below room temperature were
also investigated. I had hypothesized that at lower
temperatures glycyrrhizin would be less virucidal and that
at higher incubation temperatures glycyrrhizin would be more
virucidal. The reasoning behind this hypothesis is that the
~6 membrane would be more susceptible to the virucidal
activity of glycyrrhizin at higher temperatures because the
lipid membrane would be more fluid and therefore allow
greater potential for interaction between protein components
and glycyrrhizin.
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~ Experimental Design and Method
The general plaque assay method was used at incubation
temperatures of 2°C, 5°C, 10°C, 20°C, 30°C, 40°C and 50°C.
Percent inactivation was obtained from normalization of
PFU/ml plaque assay data obtained from control experiment
data.
The phage incubation concentration of 5 x 105 PFU/ml
was prepared and respective concentrations of O.O~M, O.l~M,
1.0~M, 10.0~M and 100.0~M of glycyrrhizin were added.
Immediatly after adding glycyrrhizin, at time t=O, the
incubation tubes; containing medium, phage and glycyrrhizin;
were placed in controlled temperature baths for 30 minutes.
Immediately after the 30 minutes, phage dilutions were made
from the incubation concentration of 5 x 105 PFU/ml to the
plating concentrations of 5 x 103 PFU/ml and 5 x 101 PFU/ml.
Appropriate volumes of host cells were added to plating
concentrations of phage, vortexed and then immediatly
plated. The control for each temperature run experiment
contained 5 x 105 PFU/ml of phage but no (O.O~M)
glycyrrhizin.
A 'Control Experiment' was performed using the plaque
assay at an incubation time of 30 minutes, an incubation
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temperature at each respective temperature indicated above,
and a phage ~6 incubation concentration of 5X105 PFU/ml with
no glycyrrhizin present. To eliminate a variable, the lOml
volume of phage used for incubation, at a concentration of
5X105 PFU/ml was, for each incubation temperature, taken
from a single dilution stock prepared at a concentration of
5X105 PFU/ml and at a volume of 200ml. The lOml of phage
was taken from the 200ml stock for each individual
incubation temperature and all individual incubations at
their respective temperatures were run simultaneously. The
same stock was used for both runs of the experiment. A
percent inactivation was calculated from data obtained from
each incubation temperature. The effects of incubation
temperature on viral infectivity was obtained. These
results were then used to normalize data obtained from
independent temperature experiments and to factor out those
effects of temperature upon phage alone. These steps allow
the derivation of what portion of the changes of virucidal
activity were due soley to temperature effects upon
glycyrrhizin.
There were two plated concentrations of phage ~6
namely, 5X103 PFU/ml and 5X101 PFU/ml with host HB10Y. Two
experimental runs were made at each plating concentration.
A count of plaques per plate was made.
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assay at an
indicated, and
five respective
~ Data Section
TABLE S-A. Incubation Temperature of 2°C.
Plaque counts per plate for phage ~6 incubated
with glycyrrhizin at 2°C.
PLAQUE COUNT PER PLATE - INCUBATION TEMPERATURE = 2°C
Plated Concentration of Phage ~6 Average
Incubation 5x103 PFU/ml 5x101 PFU/ml Normalized
Concentration to
of Plates N x 103
Glycyrrhizin #1 #2 #1 #2 PFU/ml
..
0.0 11M 20 30 0 0 25
0.1 11M 0 0 0 BP 0
1.0 11M 1 0 0 0 0
10.0 11M 0 0 0 0 0
100.0 11M NPM NPM NPM NPM ---
TABLE S-B. Incubation Temperature of SoC.
Plaque counts per plate for phage ~6 incubated
with glycyrrhizin at SoC.
PLAQUE COUNT PER PLATE - INCUBATION TEMPERATURE 5°C
Plated Concentration of Phage ~6 Average
Incubation 5xl03 PFU/ml 5x101 PFU/ml Normalized
Concentration to
of Plates N x 103
Glycyrrhizin #1 #2 #1 #2 PFU/ml
0.0 11M » 800 5 7 667
0.1 11M 0 BP 0 0 0
1.0 11M 0 0 0 0 0
10.0 11M 0 0 0 0 0
100.0 11M NPM NPM NPM NPM ---
The above data was obtained using the plaque
incubation time of 30 minutes, incubation temperature as
a phage ~6 incubation concentration of 5xl05 PFU/ml with
concentrations of glycyrrhizin.
There were two plated concentrations of phage ~6 namely, 5xl03
PFU/ml and 5x101 PFU/ml with host HB10Y. Two plates were made at each
plating concentration. A count of plaques per plate were made. An
average of PFU/ml was calculated from both plates and each plating
concentration and presented as a value normalized to Nxl03 .
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TABLE 5-C. Incubation Temperature of 10°C.
Plaque counts per plate for phage ~6 incubated
with glycyrrhizin at 10°C.
PLAQUE COUNT PER PLATE - INCUBATION TEMPERATURE = 10°C
Plated Concentration of Phage ~6 Average
Incubation 5x103 PFU/ml 5x101 PFU/ml Normalized
Concentration to
of Plates N x 103
Glycyrrhizin #1 #2 #1 #2 PFU/ml
0.0 liM »> »> 15 17 1600
0.1 liM 290 70 0 0 180
1.0 liM 0 0 0 0 0
10.0 liM 0 0 0 0 0
100.0 liM 0 0 0 0 0
TABLE 5-D. Incubation Temperature of 20°C.
Plaque counts per plate for phage ~6 incubated
with glycyrrhizin at 20°C.
PLAQUE COUNT PER PLATE - INCUBATION TEMPERATURE = 20°C
Plated Concentration of Phage ~6 Average
Incubation 5x103 PFU/ml 5x101 PFU/ml Normalized
Concentration to
of Plates N x 103
Glycyrrhizin #1 #2 #1 #2 PFU/ml
0.0 liM »> »> 69 57 6300
0.1 liM 720 620 9 7 735
1.0 liM 480 310 4 3 372.5
10.0 liM 300 100 a a 200
100.0 liM a a a a a
The above data was obtained using the plaque assay at an
incubation time of 30 minutes, incubation temperature as indicated, and
a phage ~6 incubation concentration of 5xl05 PFU/ml with five respective
concentrations of glycyrrhizin.
There were two plated concentrations of phage ~6 namely,
5x103 PFU/ml and 5x101 PFU/ml with host HB10Y. Two plates were made at
each plating concentration. A count of plaques per plate were made. An
average of PFU/ml was calculated from both plates and each plating
concentration and presented as a value normalized to NX10 3 •
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TABLE S-E. Incubation Temperature of 30°C.
Plaque counts per plate for phage ~6 incubated
with glycyrrhizin at 30°C.
PLAQUE COUNT PER PLATE - INCUBATION TEMPERATURE = 30 DC
Plated Concentration of Phage ~6 Average
Incubation 5x103 PFU/ml 5x101 PFU/ml Normalized
Concentration to
of Plates N x 103
Glycyrrhizin #1 #2 #1 #2 PFU/ml
0.0 11M »> »> 44 53 4850
0.1 11M @1000 @900 8 2 725
1.0 11M 590 610 0 6 450
10.0 11M 190 80 0 0 135
100.0 11M 0 0 0 0 0
TABLE S-F. Incubation Temperature of 40°C.
Plaque counts per plate for phage ~6 incubated
with glycyrrhizin at 40°C.
PLAQUE COUNT PER PLATE - INCUBATION TEMPERATURE = 40 DC
Plated Concentration of Phage ~6 Average
Incubation 5xl03 PFU/ml 5x101 PFU/ml Normalized
Concentration to
of Plates N x 103
Glycyrrhizin #1 #2 #1 #2 PFU/ml
0.0 11M »> »> 45 107 7600
0.1 11M »> »> 40 168 10400
1.0 11M » » 1 0 50
10.0 11M 40 50 0 0 45
100.0 11M 2 1 0 0 1.5
The above data was obtained using the plaque assay at an
incubation time of 30 minutes, incubation temperature as indicated, and
a phage ~6 incubation concentration of 5x105 PFU/ml with five respective
concentrations of glycyrrhizin.
There were two plated concentrations of phage ~6 namely,
5x103 PFU/ml and 5x101 PFU/ml with host HBlOY. Two plates were made at
each plating concentration. A count of plaques per plate were made. An
average of PFU/ml was calculated from both plates and each plating
concentration and presented as a value normalized to NX103 .
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TABLE S-G. Incubation Temperature of 50°C.
Plaque counts per plate for phage ~6 incubated
with glycyrrhizin at 50°C.
PLAQUE COUNT PER PLATE - INCUBATION TEMPERATURE = 50°C
Plated Concentration of Phage ~6 Average
Incubation 5x103 PFU/ml 5x101 PFU/ml Normalized
Concentration to
of Plates N x 103
Glycyrrhizin #1 #2 #1 #2 PFU/ml
0.0 ~M 180 90 2 a 157
0.1 ~M 22 5 a a 13.5
1.0 ~M 1 a a a 0.5
10.0 ~M a a a a a
100.0 ~M a a a a a
The above data was obtained using the plaque assay at
an incubation time of 30 minutes, incubation temperature as
indicated, and a phage ~6 incubation concentration of 5xl05
PFU/ml with five respective concentrations of glycyrrhizin.
Th~re were two plated concentrations of phage ~6
namely, 5xlO PFU/ml and 5xlO PFU/ml with host HBIOY. Two
plates were made at each plating concentration. A count of
plaques per plate were made. An average of PFU/ml was
calculated from both plates and each plating concentration
and presented as a value normalized to NXI0 3 .
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\
Data from Control and Normalization Experiments
Each of seven incubation samples were derived from the
same phage dilution and incubated at each of seven
respective temperatures. Incubation tubes did not contain
any glycyrrhizin.
TABLE 6. Temperature Control Experiment Data.
Incubation at seven respective temperatures with
the incubation concentration of phage for each
individual incubation temperature taken from the
same stock of phage dilution and no glycyrrhizin.
PLAQUE COUNT PER PLATE from TEMPERATURE CONTROL EXPERIMENT
Plated Concentration of Phage ~6 Average
5x103 PFU/ml 5x101 PFU/ml Normalized Average
to Normaliz
Incubation Experimental Run Nx10 3 Percent
Temperature #1 #2 #1 #2 PFU/ml PFU/ml
2 DC » » 36 31 3350 62%
5 DC »> »> 43 39 4100 76%
10 DC »> »> 53 48 5050 94%
20 DC »> »> 52 55 5350 100%
30 DC »> »> 49 46 4750 88%
40 DC » » 4 5 450 8%
50 DC @275 @212 2 1 190 3%
ed
The above data was obtained using the plaque assay at an
incubation time of 30 minutes, incubation temperature at each respective
temperature indicated, and a phage ~6 incubation concentration of 5x105
PFU/ml with no glycyrrhizin present. To eliminate a variable, the 10ml
volume of phage used for incubation, at a concentration of 5x105 PFU/ml
was, for each incubation temperatures taken from a single dilution stock
prepared at a concentration of 5x10 PFU/ml and at a volume of 200ml.
The 10ml of phage was taken from the 200ml stock for each individual
incubation temperature and all individual incubations at their
respective temperatures were run simultaneously. The same stock was
used for both runs of the experiment.
There were two plated concentrations of phage ~6 namely, 5x103
PFU/ml and 5x101 PFU/ml with host HB10Y. Two experimental runs were
made at each plating concentration. A count of plaques per plate were
made. An average of PFU/ml was calculated from both runs and each
plating concentration and presented as a value normalized to NX103 . The
highest PFU/ml concentration of 5350 x 103 PFU/ml occuring at 20 DC is
established as 100% and used as the denominator to calculate all other
percentages indicated.
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~ Graph section
GRAPH 2. Incubation Temperature Effects Upon
the Virucidal Activity of Glycyrrhizin and
Upon bacteriophage t6 infectivity".
Temperature Effects Upan the Virucidal
ActiVity of Glycyrrhizin & Upon Phi6
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The above inactivation curves show PFU/ml as a function of
incubation temperature. Data was obtained from using the plaque assay
at an incubation time of 30 minutes, incubation temperature at each of
seven respective temperatures as indicated, and a phage ~6 incubation
concentration of SxlOS PFU/ml with five respective concentrations of
glycyrrhizin.
There were two plated concentrations of phage ~6 namely, Sxl03
PFU/ml and Sxl01 PFU/ml with host HBIOY. Two plates were made at each
plating concentration. A count of plaques per plate were made. An
average of PFU/ml was calculated from both plates and each plating
concentration and presented as a value normalized to NxI0 3 . Each data
point is an average PFU/ml at a respective incubation temperature and
respective incubation concentration of glycyrrhizin. Each curve is at a
respective incubation temperature.
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GRAPH 3. Incubation Temperature Effects Upon
bacteriophage ~6 infectivity.
Temperature Control Experiment.
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The above inactivation curves show PFU/ml as a function of
incubation temperature. Data was obtained from using the plaque assay
at an incubation time of 30 minutes, incubation temperature at each of
seven respective tem~eratures as indicated, and a phage ~6 incubation
concentration of 5xlO PFU/ml.
There were two plated concentrations of phage ~6 namely, 5xl03
PFU/ml and 5xlO l PFU/ml with host RB10Y. Two plates were made at each
plating concentration. A count of plaques per plate were made. An
average of PFU/ml was calculated from both plates and each plating
concentration and presented as a value normalized to NX103 . Each data
point is an average PFU/ml at a respective plated phage concentration
and number of plates. Each curve is at a respective incubation
temperature.
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~ Results Summary
without any virucidal compound, phage incubation
temperature alone has an effect upon the potential of viral
infectivity. without any virucidal compound, phage
incubation temperatures above and below room temperature
show a percent inactivation. These results were obtained
from the incubation temperature control experiments and
these data were used to normalize temperature effects upon
phage alone. Letting 100% be set for the highest PFU/ml
plaque count, which is room temperature, the drop in plaque
forming units can be seen at temperatures above and below
room temperature result in the percent inactivation curve
shown in Graph No.3. From Data Graph No.3, obtained from
incubation temperature control results one can see that
neither of the two curves above or below room temperature,
which show a decrease in plaque formation, are linear. Also
the rate of decrease of plaque formation for each of the
two curves is not equal. From incubation temperature control
results one can see that incubation temperatures above room
temperature show a greater reduction in plaque formation to
the point of significant virucidal action due to the effects
of increased temperature alone (i.e. without any antiviral
compound) . The effects of temperature on phage alone must
be factored out of and used to normalize the experimental
results obtained from the individual temperature runs
effecting the antiviral activity of glycyrrhizin and phage.
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The first thing to observe in Graph No. 2 is that the
plaque forming units for O.O~M of glycyrrhizin all start out
at different values. This is simply because each 'per
temperature' run of phage concentration for incubation were
made separately and at individual times. All O.O~M values
for PFU/ml results are all on the same order, and in fact
only differ by a simple factor of n. This is tabularized in
the following Table 7.
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TABLE 7. Data from Controls in Independent Temperature Runs
Plaque-Counts PFU/ml Normaliz~d to a
Factor of 'n', whereby n x 10 ; the mantissa
is the n-factor and 103 is the exponent.
NORMALIZED CONTROL DATA FROM INDEPENDENT TEMPERATURE RUNS
Temperature
2°C
5°C
10°C
20°C
30°C
40°C
50°C
(n-factor) x 103
25
667
1600
6300
4850
7600
157
These control experiments contained no glycyrrhizin and
incubation temperature was the only variable. The data in
Table 7 were obtained from data in Table 6.
It is these values above that will be used as a
normalized standard along with the percentage results found
in Table 6 and obtained in the temperature control
experiments. Control data from the 20°C Temperature Run is
the highest PFU/ml value and is set as the 100% normalized
value. All other data points for each Temperature Run are
adjusted to the normalization results calculated from the
control experiment. Table 8-A and Table 8-B display the
calculated steps to obtain the Normalization MUltiplier used
to normalize Tables 5-A through 5-G into Table 9.
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TABLE a-A. Anticipated n-factor Based on Contol Experiment
Results and the Normalization of the Maximum
Plaque Count Among all Control Data Values
from Each Independent Temperature Run Experiment.
CALCULATIONS TO OBTAIN ANTICIPATED N-FACTOR
FOR EACH TEMPERATURE RUN EXPERIMENT
BASED ON CONTROL EXPERIMENT NORMALIZED PERCENTAGES
Average Maximum Anticipated n-factor
Normalized Normalized for Temperature Run
Percent PFUjml value Experiments Based
from the out of all the On Control Experiment
Control Temperature Runs' and Maximum Contol
Temperature Experiment. Control Data. Value from Temp. Runs
2°C 62% x 6300 = 3900
5°C 76% x 6300 4780
10°C 94% x 6300 = 5920
20°C 100% x 6300 = 6300
30°C 88% x 6300 = 5540
40°C 8% x 6300 = 500
50°C 3% x 6300 190
Because of the Control Experiment we know the
percentage roll-off above and below 20°C. The percentage
roll-off is the 'Normalized Percent' obtained from averaging
values in the Control Experiment found in Table 6. We also
know what Temperature Run Control Data has the highest or
maximum PFU/ml value. This maximum PFU/ml value from the
controls occurs in the independent 20°C Incubation
Temperature Run and is 6300 normalized to the plated
concentration of n x 103 PFU/ml. If all other variables
were equal and held constant between independent temperature
runs; then we should obtain the 'Anticipated n-factor' by:
( Anticipated n-factor) = (Normalized Percent ) x
(Maximum Temperature Run Control Value)
Table 8-A contains all of the calculated 'Anticipated
n-factors'. These values are carried over into Table 8-B
and further used to calculate the Normalization MUltiplier.
The Normalization MUltiplier is the value, per each
Temperature Run Experiment (i.e. 2°C, 5°C, ... , 50°C), by
which all data points in that temperature run are mUltiplied
by to obtain the normalized data table. The Normalized Data
Table 9 can then yield percent inactivations which show only
temperature effects upon virucidal activity of glycyrrhizin
alone.
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TABLE a-B. Normalization MUltiplier Calculations
Using the result Data From Table a-A and
the Original n-factor from Table 7 we
derive the Normalization MUltiplier.
CALCULATION OF NORMALIZATION MULTIPLIER
FOR FACTORING OUT TEMPERATURE EFFECTS
FROM ALL TEMPERATURE RUN DATA
Anticipated n-factor Original
for Temperature Run n-factor
Experiments Based from each of
On Control Experiment the Temperature
and Maximum Contol Runs' Control
Value from Temperature Data (Table 7.)
Temperature Runs (Table a-A.) n x 103
Normalization
Multiplier
for removing
effects of
Temperature
from all data
in Temp. Runs
2°C
5°C
10°C
20°C
30°C
40°C
50°C
3900 (= / +) 25 (x / =)
4780 (= / +) 667 (x / =)
5920 (= / +) 1600 (x / =)
6300 (= / +) 6300 (x / =)
5540 (= / +) 4850 (x / =)
500 (= / +) 7600 (x / =)
190 (= / +) 157 (x / =)
156.0
7.2
3.7
1.0
1.14
0.07
1.2
The 'Normalization MUltiplier' is a mUltiplicand for
each independent temperature run that is used to mUltiply
every data point in that temperature run so as to factor out
effects of temperature on phage alone and to normalize
control data between each individual temperature run. The
'Normalization MUltiplier' is obtained by asking what value
was the 'Original n-factor' from Temperature Run Control
Data multiplied by to obtain the 'Anticipated n-factor' for
Temperature Run Control Data'.
k x ( Original n-factor ) = ( Anticipated n-factor
or by algebraically rearranging terms we obtain:
Anticipated n-factor
-------------------- =
Original n-factor
k·,
where k is the 'Normalization MUltiplier'.
Each Normalization MUltiplier is mUltiplied by averaged
values in its respective Temperature Run Table. The
Normalization MUltiplier for 2°C is 156.0. Hence, 156.0
mUltiplies each averaged value found in Table 5-A (the 2°C
Incubation Temperature Run). The results of this operation
50
are found in the 2°C column of Table 9. This is done for
each temperature.
For example, all the results for Table 5-A, 2°C
incubation temperature, will be multiplied by 156 to
normalize out phage incubation concentration differences
existing between each independent temperature run and to
factor out effects of temperature upon phage alone (no
glycyrrhizin). These adjustments result in normalized data
values for each data point arising from seven temperatures
and five concentrations of glycyrrhizin. These are
displayed in Table 9. In addition Table 9 contains percent
inactivation values obtainable from these normalizations.
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TABLE 9. Normalized Temperature Effects upon Virucidal
Activity of Glycyrrhizin upon Phage 16
Table 9 combines all data normalized from each
independent Temperature Run Data Table 5-A through
5-G by mUltiplying the 'Normalization MUltiplier'
found in Table 8, for each respective temperature,
by each averaged plaque count in each Table 5-A
to 5-G for each concentration of glycyrrhizin.
All plaque values have been normalized to
n x 101 PFUIml.
AVERAGED AND NORMALIZED PLAQUE COUNT PER PLATE
AND PERCENT INACTIVATION
Glycyrrhizin TEMPERATURE RANGE
Incubation
Concentration 2°C 5°C 10 0 C 20 0 C 30 0 C 40 0 C 50 0 e
O.OJ.lM 39.0 47.8 59.2 63.0 55.4 5.0 1.9
%Inactivation 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
O.lJ.lM 0.0 0.0 5.3 7.4 8.27 7.3 0.162
%Inactivation 0.0% 100.0% 91.0% 88.2% 85.0% 91.4%
1.0J.lM 0.0 0.0 0.0 3.7 5.13 0.6 0.0
%Inactivation 100.0% 100.0% 100.0% 94.1% 90.7% 88.0% 100.0%
10.0J.lM 0.0 0.0 0.0 1.0 0.91 0.3 0.0
%Inactivation 100.0% 100.0% 100.0% 98.4% 98.3% 94.0% 100.0%
100.0J.lM NPM NPM 0.0 0.0 0.0 0.01 0.0
%Inactivation 100.0% 100.0% 100.0% 99.76% 100.0%
Table 9 combines all data normalized from each independent
Temperature Run Data Table 5-A through 5-G by multiplying the
'Normalization Multiplier' found in Table 8, for each respective
temperature, by each averaged plaque count in each Table 5-A to 5-G for
each concentration of glycyrrhizin. All plaque values have been
normalized to n x 101 PFU/ml.
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Graph 4. Normalized Temperature Effects upon Virucidal
Activity of Glycyrrhizin upon Phage 16
Temperature Effects on the Virucidal
Activity of Glycyrrhizin upon Phi6
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Graph 4 displays the normalized percent inactivation curve for
each independent temperature experiment. The plaque assay was performed
under seven different incubation temperatures. Data for each curve has
been normalized so as to factor out temperature effects on phage during
incubation and any variable differences between phage concentrations in
each temperature run. Data for the graph was obtained from Table 9.
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~ Conclusions and Discussion
The effects of temperature on both glycyrrhizin and w6
can are seen in the Graph 2. The effects of temperature
upon w6 alone (i.e. no glycyrrhizin) can be seen clearly in
Graph 3. Looking at Graph 3 it is seen that at
temperatures above and below 20°C the PFU/ml plaque count
drops. The number of plaques decreases more rapidly at
temperatures above 20°C than those below 20°C. Most likely
the higher temperatures have more of a virucidal effect
whereas the results below 20°C display more of a reduced
infectivity potential while maintained at the lower
temperatures. Recall that w6 phage is stored long term (4-
6 months) at 2°C. All room temperature inactivation
experiments, allowed incubation tubes, containing phage,
to first reach and sit at room temperature prior to
commencement of incubation and certainly therfore prior to
actual plating. Host infection takes place during plating.
It is during plating that host and phage are vortexed
together in the cooling agar. Obviously virus is not
inactivated at lower temperatures but has a reduced
potential for infectivity when incubated and then immediatly
plated while at the lower temperatures. Bacteriophage w6 is
however partially inactivated when incubated at the higher
temperatures. Experimental data, which are not included
here, were obtained to allow phage incubated at higher
temperatures to cool down to and sit at room temperature.
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At various intervals of cooling sample plates where made.
After reaching room temperature sample plates where made at
six 15 minute intervals in order to observe if any plaque
forming units increase. The results of these experiments
showed that there was no appreaciable increase in viral
infectivity or plaque forming units as a result of allowing
incubated phage to cool to room temperature and even sit at
room temperature for 2-3 hours.
After the normalization results of Table 4 (Graph 3)
are applied to temperature data of Table 3 (Graph 2) and all
effects of temperature acting on ~6 are normali.zed out then
the effects of temperature on glycyrrhizin virucidal
activity can be observed. The calculations from the results
section yield the Table 9 and Graph 4. One can see that
the virucidal activit of glycyrrhizin is not appreciably
affected by temperature changes within a range from 2°C to
50°C. The ihcubation temperatures below 20°C however, show
a slightly higher percent inactivation at O.l~M of
glycyrrhizin. There is a peculiar data point in all graphs
occuring at 0.1 ~M of glycyrrhizin for the 40°C run, a
temperature above 20°C, where percent inactivation still
remains at approximately 0%. Several experiments were
peformed above and below the O.l~M concentration of
glycyrrhizin. Inactivation results fluctuate around the
O.l~M data point. This is because of the slope of the
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percent inactivation curve typical in this region of a
sigmoidal curve. The percent inactivation of ~6 by
glycyrrhizin increases very slightly as incubation
temperature decreases at the data point O.l~M. This is only
due to fluctuation errors about this data point and not
actual effects of temperature on glycyrrhizin at this data
point. Temperature has more of an effect on ~6 directly
than on glycyrrhizin virucidal activity. Temperature has no
appreciable effect on glycyrrhizin activity.
All data points involving 0.1 ~M glycyrrhizin for 40°C
do not show the consistent percent inactivation as seen at
all other temperatures. This could be an interesting
phenomenon or simply an experimental error. Repeat
experiments, as stated above, would occasionally show
similar fluctuations at various temperatures including 20°C.
This phenomenon, if not characteristic of the sigmoidal
curve in this region, is then most likely due to an error in
lab technique. There may be some indication of intermitant
activity at or below some critical level such as O.l~M of
glycyrrhizin.
This phenomenon might become more evident or occur more
regularly at higher temperatures. Since, however, the
virucidal effects of temperature are very prevalent at 50°C,
temperatures above 50°C would outweigh virucidal effects of
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glycyrrhizin.
In summary the expected effects of temperature do
occur. Results show that just incubating phage alone, at
temperatures above and below room temperature, have an
effect on phage infectivity. After effects of temperature
on phage are factored out, one can see that changes in
incubation temperature have no appreciable effect on the
virucidal activity of glycyrrhizin upon ~6. Glycyrrhizin
maintains a relatively consistant inactivation curve through
a temperature range between 2°C and 50°C.
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3. Effects of Exogenous Lipids upon the Virucidal Activity
of Glycyrrhizin upon ~6
~ Rationale and Hypothesis
In an in-vivo system the activity of a potential
antiviral compound becomes more complex. The interaction
of numerous molecules increase the number of variables that
affect, in a positive or negative way, the potential of an
antiviral compound. In an attempt to be able to measure and
control individual variables and yet add one degree of
complexity, individual exogenous lipids were added and
present in incubation tubes containing phage before the time
of adding and incubating with the virucidal compound
glycyrrhizin. Effects due to the addition of a single
exogenous lipid were measured. six different exogenous
lipids were tested. Previous work investigating
interference effects on virucide activity had shown that
certain fatty acids and in general exogenous lipids could
interfere with a virucidal compound (20). certain virally
noninactivating and noninhibiting fatty acids were potent
interfering agents (20). I am postulating here that even
inactivating fatty acids could interfere with another
virucidal agent, therefore exogenous lipids were selected
for interference study in this research. I had hypothesized
that the exogenous lipids would have definite effects on
glycyrrhizin. I had mostly expected that these lipids would
interfere and reduce the virucidal activity of glycyrrhizin.
Individual lipids that did interefere could
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implicate
mechanisms
modifying
agent.
whereby
variable
the presence of other molecules add a
to the effectiveness of a virucidal
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~ Experimental Design and Method
All experiments were performed at room temperature.
The incubation concentration for all experiments was 5 x 105
PFU/ml and the plated concentrations of phage was 5 x 10 2,
5x 101 PFU/ml and 5x 100 PFU/ml. Phage were added to
incubation tubes first. Each respective exogenous lipids
was then added to the incubation tubes and heavily vortexed
at each of the respective concentrations. Incubation tubes
were allowed to sit for 30-45 seconds before adding
glycyrrhizin. The virucidal compound, glycyrrhizin was
added to the incubation tubes at a constant concentration of
10~M and then vortexed. Time t=o began immediatly after the
glycyrrhizin was added and vortexed. The incubation time,
It, was 30 minutes. A single run was made for each
exogenous lipid. Two plates per plating concentration were
made. The control plates contained only phage. Neither the
respective exogenous lipid nor virucidal compound were added
to the control plates. All incubation tubes were made from
equal 10ml volumes from the same stock concentration of
phage. This was done so that each incubation sample as well
as controls came from the same dilution lineage. Three
exogenous lipid runs were performed at the same time and
from the same phage stock. An average was taken between the
first set of three and an average for the second set of
three exogenous lipids controls to yield a more accurate
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control value. These two averages yielded a ratio for
deriving a complete table of percent inactivation based on
0.0 ~M of the exogenous lipid and 10.0~M of the antiviral
compound glycyrrhizin.
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~ Data section
TABLE lO-A. Phosphatidyl Choline Effects on Glycyrrhizin
Effects of Phosphatidyl Choline on the Virucidal
Activity of Glycyrrhizin upon phage ~6.
PLAQUES PER PLATE - PHOSPHATIDYL CHOLINE
PLATED CONCENTRATIONS (PFU/ml)
Incubation
Concentration 5x103 5x101 5x100 Average
of Plaque Count
Phosphatidyl PLATES Normalized to
Choline 1 2 1 2 1 2 nx100 PFU/ml
CONTROL » » 74 61 8 11 8.12
O.OJlM 71 82 1 0 0 0 0.084
1.0JlM 650 700 8 6 0 0 0.688
10.0JlM » » 66 91 5 5 6.43
100.0JlM » » 82 105 4 5 7.00
Control plates contained O.OJlM of the respective exogenous lipid
and O.OJlM of glycyrrhizin.
The
incubation
incubation
plate, and
above data was obtained using the plaque assay
time of 30 minutes, incubation temperature of
concentration of glycyrrhizin of 10JlM except for
a phage ~6 incubation concentration of 5xl05 PFU/ml.
at an
20°C,
control
There were three plated concentrations of phage ~6 namely, 5x103
PFU/ml, 5x101 PFU/ml, and 5x100 PFU/ml with host HB10Y. Two plates at
each concentration were made. There were 4 concentrations of the
respective exogenous lipid. A count of plaques per plate was made. An
average was calculated from plaque count data from all plated
concentrations and both plates and normalized to the nx10 0 PFU/ml plate
count.
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TABLE lO-B. Arachidylic Acid Effects on Glycyrrhizin
Effects of Arachidylic Acid on the Virucidal
Activity of Glycyrrhizin upon phage ~6.
PLAQUES PER PLATE - ARACHIDYLIC ACID
PLATED CONCENTRATIONS (PFUjm1)
Incubation
Concentration 5x103 5x101 5x100 Average
of Plaque Count
Arachidylic PLATES Normalized to
Acid 1 2 1 2 1 2 nx100 PFUjml
CONTROL »> »> 101 69 8 6 7.75
O.O~M 80 65 1 0 0 0 0.082
1.0~M » » 11 9 1 1 1.0
10.0~M »> »> 97 94 10 8 9.27
100.0~M CD CD 115 85 10 17 11. 75
Control plates contained O.O~M of the respective exogenous lipid
and O.O~M of glycyrrhizin.
The
incubation
incubation
plate, and
above data was obtained using the plaque assay
time of 30 minutes, incubation temperature of
concentration of glycyrrhizin of 10~M except for
a phage ~6 incubation concentration of 5x105 PFUjml.
at an
20°C,
control
There were three plated concentrations of phage ~6 namely, 5x103
PFUjm1, 5x101 PFUjml, and 5x100 PFUjml with host HB10Y. Two plates at
each concentration were made. There were 4 concentrations of the
respective exogenous lipid. A count of plaques per plate was made. An
average was calculated from plaque count data from all plated
concentrations and both plates and normalized to the nx100 PFUjml plate
count.
LH8
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TABLE lO-C. Cholesterol Effects on Glycyrrhizin
Effects of Cholesterol on the Virucidal
Activity of Glycyrrhizin upon phage ~6.
PLAQUES PER PLATE - CHOLESTEROL
PLATED CONCENTRATIONS (PFU/ml)
Incubation
Concentration 5x103 5x101 5x100 Average
of Plaque Count
Cholesterol PLATES Normalized to
1 2 1 2 1 2 nx100 PFU/ml
CONTROL »> »> 128 115 13 9 11.58
O.Oj.lM 110 106 1 0 0 0 0.105
1.0j.lM 770 580 7 4 0 0 0.613
10.0j.lM » » 19 11 0 0 1.5
100.0j.lM »> »> 41 24 0 0 3.25
Control plates contained O.Oj.lM of the respective exogenous lipid
and O.Oj.lM of glycyrrhizin.
The
incubation
incubation
plate, and
above data was obtained using the plaque assay
time of 30 minutes, incubation temperature of
concentration of glycyrrhizin of 10j.lM except for
a phage ~6 incubation concentration of 5x105 PFU/ml.
at an
20°C,
control
There were three plated concentrations of phage ~6 namely, 5x103
PFU/ml, 5x101 PFU/ml, and 5x100 PFU/ml with host HB10Y. Two plates at
each concentration were made. There were 4 concentrations of the
respective exogenous lipid. A count of plaques per plate was made. An
average was calculated from plaque count data from all plated
concentrations and both plates and normalized to the nx10 0 PFU/ml plate
count.
LH8
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TABLE 10-D. stearic Acid Effects on Glycyrrhizin
Effects of stearic Acid on the Virucidal
Activity of Glycyrrhizin upon phage ~6.
PLAQUES PER PLATE - STEARIC ACID
PLATED CONCENTRATIONS (PFU/ml)
Incubation
Concentration 5x103 5x101 5x100 Average
of Plaque Count
Stearic PLATES Normalized to
Acid 1 2 1 2 1 2 nx100 PFU/ml
CONTROL »> »> 55 68 6 5 5.9
O.01JM 65 71 0 0 0 0 0.068
1.01JM 1 2 0 0 0 0 0.0015
1O.01JM 0 0 0 0 0 0 0.0
100.01JM NHL NHL BP NHL 0 0 ---
Control plates contained O.01JM of the respective exogenous lipid
and O.01JM of glycyrrhizin.
The above data was obtained using the plaque assay at an
incubation time of 30 minutes, incubation temperature of 20°C,
incubation concentration of glycyrrhizin of 101JM except for control
plate, and a phage ~6 incubation concentration of 5x105 PFU/ml.
There were three plated concentrations of phage ~6 namely, 5x103
PFU/ml, 5x101 PFU/ml, and 5x100 PFU/ml with host HB10Y. Two plates at
each concentration were made. There were 4 concentrations of the
respective exogenous lipid. A count of plaques per plate was made. An
average was calculated from plaque count data from all plated
concentrations and both plates and normalized to the nx100 PFU/ml plate
count.
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TABLE lO-E. Oleic Acid Effects on Glycyrrhizin
Effects of Oleic Acid on the Virucidal
Activity of Glycyrrhizin upon phage ~6.
PLAQUES PER PLATE - OLEIC ACID
PLATED CONCENTRATIONS (PFU/ml)
Incubation
Concentration 5x103 5x101 5x100 Average
of Plaque Count
Oleic PLATES Normalized to
Acid 1 2 1 2 1 2 nx100 PFU/ml
CONTROL »> »> 49 58 6 6 5.8
O.OIlM 69 44 0 0 0 0 0.057
l.°IlM 410 350 8 7 0 0 0.565
10.01lM 2 3 0 0 0 0 0.0025
100.01lM NHL NHL 0 0 0 0 ---
Control plates contained O.OIlM of the respective exogenous lipid
and O.OIlM of glycyrrhizin.
The
incubation
incubation
plate, and
above data was obtained using the plaque assay
time of 30 minutes, incubation temperature of
concentration of glycyrrhizin of lOIlM except for
a phage ~6 incubation concentration of 5x105 PFU/ml.
at an
20°C,
control
There were three plated concentrations of phage ~6 namely, 5x103
PFU/ml, 5x101 PFU/ml, and 5x100 PFU/ml with host HB10Y. Two plates at
each concentration were made. There were 4 concentrations of the
respective exogenous lipid. A count of plaques per plate was made. An
average was calculated from plaque count data from all plated
concentrations and both plates and normalized to the nx100 PFU/ml plate
count.
LH8
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TABLE lO-F. caprylic Acid Effects on Glycyrrhizin
Effects of Caprylic Acid on the Virucidal
Activity of Glycyrrhizin upon phage ~6.
PLAQUES PER PLATE - CAPRYLIC ACID
PLATED CONCENTRATIONS (PFU/ml)
Incubation
Concentration 5x103 5x101 5x100 Average
of Plaque Count
Caprylic PLATES Normalized to
Acid 1 2 1 2 1 2 nx100 PFU/ml
CONTROL »> »> 46 44 4 7 4.71
O.OpM 41 83 a a a a 0.062
1.0pM 10 17 a a a a 0.0135
10.0pM a a a a a a 0.0
100.0pM NHL NHL BP NHL a a ---
Control plates contained O.OpM of the respective exogenous lipid
and O.OpM of glycyrrhizin.
The
incubation
incubation
plate, and
above data was obtained using the plaque assay
time of 30 minutes, incubation temperature of
concentration of glycyrrhizin of 10pM except for
a phage ~6 incubation concentration of 5xl05 PFU/ml.
at an
20°C,
control
There were three plated concentrations of phage ~6 namely, 5x103
. PFU/ml, 5x101 PFU/ml, and 5x100 PFU/ml with host HB10Y. Two plates at
each concentration were made. There were 4 concentrations of the
respective exogenous lipid. A count of plaques per plate was made. An
average was calculated from plaque count data from all plated
concentrations and both plates and normalized to the nx100 PFU/ml plate
count.
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TABLE 11. Effects of Exogenous Lipids on Virucidal
Activity of Glycyrrhizin upon phage 16
Expressed as A Percent Inactivation
PERCENT INACTIVATION
EXOGENOUS LIPID
Incubation Arachidylic stearic Oleic Caprylic
Concentration PC(l) Acid Cholesterol Acid Acid Acid
CONTROL 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
O.O~M 99.0% 99.0% 99.0% 98.86% 98.86% 98.86%
1.0~M 92.5% 89.1% 93.3% 99.9% 89.7% 99.8%
10 ~M 39.6% -1.4% 83.6% 100% 99.9% 100%
100~M 22.5% -28.6% 64.4%
Control plates contained O.O~M of the respective exogenous
and O.O~M of glycyrrhizin.
lipid
at an
20°C,
control
There
lipid
percent
The above data was obtained using the plaque assay
incubation time of 30 minutes, incubation temperature of
incubation concentration of glycyrrhizin of 10~M except for
plate, and a phage ~6 incubation concentration of 5x10 5 PFU/ml.
were four concentrations of each of the respective exogenous
namely; O.O~M, 1.0~M, 10.0~M, and 100.0~M. Data used to derive
inactivation values were obtained from Tables 10-A through 10-F.
(1) PC is Phosphatidyl Choline.
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~ Graph section
GRAPH S. Effects of Exogenous Lipids on virucidal
Activity of Glycyrrhizin upon phage 16
Expressed as ~ change in Percent Inactivation
Effects of Exogenous Lipids on Virucide
Activity of Glycyrrhizin on Phl6
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Concentration values of O.O~M of the respective
exogenous lipid and O.O~M of glycyrrhizin were used as
controls.
Data for the above graph was taken from Table 11. Data
was obtained using the plaque assay at an incubation time of
30 minutes, incubation temperature of 20°C, incubation
concentration of glycyrrhizin of 10~M except for contro~
plate, and a phage ~6 incubation concentration of 5x10
PFU/ml. There were four concentrations of each of the
respective exogenous lipid namely; O.O~M, 1.0~M, 10.0~M, and
100.0~M. Data used to derive percent inactivation values in
Table 11 were obtained from Tables 10-A through lO-F.
(1) PC is Phosphatidyl Choline.
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~ Results Summary
Phosphatidyl choline, arachidylic acid, and cholesterol
show virucidal neutralizing effects upon glycyrrhizin.
stearic
appreciable
glycyrrhizin.
acid, oleic
virucidal
acid, caprylic acid show no
neutralizing effects upon
Arachidylic acid showed the most effective virucidal
neutralizing effect on the virucidal compound glycyrrhizin
of all the lipids tested.
Virucidal neutralizing effects for phosphatidyl
choline, arachidylic acid, cholesterol and stearic acid
begin at 1.0~M concentrations. Virucidal neutralizing
effects sharply increase for arachidylic acid immediately
after concentrations of 1.0~M. Virucidal neutralizing
effects of oleic acid only appear slightly at a
concentration of 1.0~M.
There is no observable virucidal neutralizing effects
for neither stearic acid nor caprylic acid at any
concentrations tested. Phosphatidyl choline shows the
second most effective and cholesterol the third most
effective virucidal neutralizing effect on the virucidal
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compound glycyrrhizin of all the lipids tested.
It has not been fully investigated here, but there is
some indication that stearic acid, caprylic acid and
especially oleic acid were showing, instead of a
neutralizing effect upon glycyrrhizin, a possible slight
virucidal effect in addition to the virucidal activity of
glycyrrhizin. The higher concentrations of stearic acid,
oleic acid and caprylic acid are most likely having a
cytotoxic effect because the higher concentrations of these
lipids consistently either inhibited growth or exhibited
abnormal growth of host lawn. These higher incubation
concentrations will yield higher concentrations in culture.
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~ Conclusions and Discussion
The effects of phosphatidyl- choline, arachidylic acid,
and cholesterol upon the virucidal activity of glycyrrhizin
has been termed in a general sense as 'virucidal
neutralizing'. These compounds are more specifically ·and
most likely providing a protective action against
glycyrrhizin especially because they are present in
incubation tubes before glycyrrhizin is added. I do not
believe that there is any enzymatic chemistry taking place
between these protective lipids and glycyrrhizin but rather
molecular interactions.
since it has already been shown that the virucidal
activity of glycyrrhizin would occur without any lipid
present, virucidal activity would therefore certainly occur
prior to the addition of lipid. Consequently the lipid
would need to be present in the incubation tube prior to
adding glycyrrhizin.
In attempting to identify areas of further and follow-
up research, I would find it interesting to perform an
experiment that has a control with phage but no glycyrrhizin
and no lipid and a second incubation tube where at time t=o
only phage and glycyrrhizin are present. At time t=15
minutes, lipid is added to the second tube for the remaining
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15 minutes. Plates would be made from both tubes at time
t=30 minutes. A third plate would be made from the first
control tube. The top agar tube for the third plate
(t=30min+) would contain lipid along with the host and top
agar and has been vortexed prior to adding phage. Once
phage is added the agar tube would then be vortexed and
immediately plated. A third tube would contain lipid and
glycyrrhizin and would incubate for 30 minutes. Phage would
be added at time t=30 minutes, immediately vortexed, diluted
and plated. As done-in this research phage and lipid would
be present in a fourth incubation tube before adding
glycyrrhizin (t=O-). Total incubation time for all
incubation tubes would be 30 minutes at which point plates ~
for each incubation tube would be made. Plates would also
be made from all incubation tubes at t=14 minutes and t=29
minutes just prior to the addition of lipid to tube 2 and
phage to the lipid-host-top-agar tube. This would provide
further evidence if neutralizing effects of these lipids are
protective, arresting or both and to what degree of either.
Before speculating on the molecular interactions of
lipid and glycyrrhizin, which may be responsible for the
protective effects of the lipid, the following molecular
structures for phosphatidyl choline, arachidylic acid,
cholesterol and again glycyrrhizin are shown for comparison
in Diagram 4.
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Diagram s. Molecular structure of protective exogenous lipids
used-in this section of this reasearch.
Phosphatidyl Choline
Arachidylic Acid
Cholesterol
Glycyrrhizin
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An important question to ask is: are there any common
molecular characteristics that allow these three molecules
to interact with glycyrrhizin and thereby provide a
virucidal protective mechanism?
possible common motifs?
If so, what are the
Arachidylic acid, cholesterol and glycyrrhizin all have
an OH group off of a carbon molecule. The OH group off of
the carbon molecule of glycyrrhizin is involved in the
glycoside linkage to sugars. In the glycoside form the
gelling properties of glycyrrhizin are very apparent. The
glycoside form
plant source.
of glycyrrhizin naturally occurs in its
Recall that the lipid envelope of the phage ~6 contains
PG which is also a phosphatide as is pc. This fact may
suggest some similar interactions between glycyrrhizin with
the phage envelope and glycyrrhizin with the protective
mechanisms of pc.
Glycyrrhizin may be interacting with a given lipid by
molecule molecule interaction;
way of one
..
..
of the following speculative models:
lipid-
micelle::glycyrrhizin-attachment; or amorphous aggregations
of lipids, medium salts, and glycyrrhizin. Each individual
. lipid may have a different method of interaction.
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Diagram 6. Speculative Models of Exogenous Lipid and
Glycyrrhizin Interaction.
Lipid molecule to Glycyrrhizin Molecule Interaction
Glycyrrhizin
Lipid Micelle Formation and Glycyrrhizin Surface Attachment
Lipid and Glycyrrhizin Molecule Aggregations
c; ly(yrr~~i'"
,
•Oyer' GlY'Yf1'~;li~
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A peculiar result is that arachidylic acid is among the
most active of virucidal neutralizing lipids. Cholesterol
is somewhat similar in structure and size to glycyrrhizin
and may form a semi-semetrically sized structure about a
bond between hydroxal groups that each molecule contains.
The neutralizing lipid PC is similar to the the viral lipid
envelope PG. Speculating that glycyrrhizin is interacting
with PG of the phage envelope, and that PG might be involved
in events that lead to P3 dislodgement during phage
inactivation, I would postulate that glycyrrhizin may
interact with PC and reduce its involvement with PG in the
viral envelope and hence reduce the virucidal activity of
glycyrrhizin. Arachidylic acid is different than PG and
chosterol and more like the other lipids tested which did
not show a great neutralizing or protective level against
the virucidal agent glycyrrhizin. One characteristic of
arachidylic acid, which might contribute to its virucidal
neutralizing ability and does distinguish its structure from
the other lipids tested is that it does have 4 unsaturated
bonds along with its characteristic fatty acid tail.
The interaction of glycyrrhizin with each of these
lipids may be different. PC may interact by micelle
formation; arachidylic acid may interact by glycoside
linkages; and cholesterol may interact by aggregation. All
these interactions may involve or require certain factors in
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the host medium or other medium properties such as ions, pH
and temperature.
Another possible mechanism may involve the interaction
of these lipids with the surface of phage ~6 in such a way
as to ultimately protect P3 and P6 envelope protein from
glycyrrhizin. This possible mechanism includes lipid
molecules blocking and thereby protecting the area of the ~6
attachment protein from glycyrrhizin. Another possible
mechanism is that the protective lipids attract glycyrrhizin
away from the ~6 surface proteins dissallowing
glycyrrhizin to interact. The interaction of protective
lipid and glycyrrhizin may not be by way of a mutual
molecular bond. A chemical action upon an active site of
glycyrrhizin may be occuring.
The protective lipids may be interacting with the
phage envelope and thereby reduce the fluidity of the lipid
envelope. This reduction in the fluidity of the lipid
membrane of the phage may prevent further intercalation or
interaction by glycyrrhizin. The lipid envelope of the
phage may have a higher affinity for this affect by the
exogenous lipid than the glycyrrhizin. This affect may be
stablized by the pre-exposure to the protective lipids
before glycyrrhizin.
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By whatever mechanism that these lipids inhibit the
virucidal activity of glycyrrhizin, these mechanisms do not
completely disrupt or interfere with viral infectivity.
In the next section several incubation experiments each
with a different concentration of glycyrrhizin and a
constant concentration of each individual protective lipid
are performed. Follow-up research should investigate
several concentrations of each individual lipid with several
concentrations of glycyrrhizin for each lipid concentrations
in both host medium (which contains salts, nutrients, etc .. )
and in distilled water as the incubation solvent. By
performing these experiments the neutralizing ratios may be
better established and would also determine if any factors
are contributed by host growth medium. Experiments with
only phage and exogenous lipid would allow the determination
of virucidal activity of any of these exogenous lipids.
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4. The effects of increased concentrations of glycyrrhizin
in the presence of a protective level of an
exogenous lipid.
~ Rationale and Hypothesis
In the previous set of experiments I investigated the
effects of six exogenous lipids and their effects upon the
virucidal activity of glycyrrhizin at 10~M. In my results I
noted that three of the six exogenous lipids did show
protective or neutralizing effects upon glycyrrhizin. I
also observed from those results at what concentrations each
of .the effective·neutralizing exogenous lipids began to show
an appreciable effect. In this set of experiments I have
selected and held constant the concentration of the
exogenous lipids, where appreciable neutralizing activity
was observed, while increasing the concentration of the
virucidal compound glycyrrhizin in order to determine
possible recovery of a virucidal activity. I had
hypothesized that increasing concentrations of glycyrrhizin
would overcome the protective effects of the exogenous
lipids. I also wanted to determine if a concentration ratio
between lipid and glycyrrhizin existed where 50% viral
inactivation occurs. This parameter would indicate a
critical concentration ratio or critical IRa/n value.
Recall that IRa/n is the incubation ratio of an antiviral
concentration to an 'antiviral neutralizing' concentration.
The critical. IRa/n would be where virucidal
reduced by 50%.
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activity is
~ Experimental Design and Method
First, 160 ml of 5x 105 PFU/ml phage solution is
prepared. The 160ml is divided eqaully into 16 sterile
incubation tubes containing 10ml each which still is at a
phage concentration of 5 x 105 PFU/ml.
A 4x4 matrix of incubation tubes is setup and prepared
to contain the following final additives:
Tube #1 Tube #2 Tube #3 Tube #4
O.OpM Glyz. O.OpM Glyz.
No lipd No Li~id
sx10S PFU/ml ~6 sx10 PFU/ml ~6
100pM Glyz.
No Li~id
sx10 PFU/ml ~6
lmM Glyz
No Li~id
Sx10 PFU/ml &lJ6
Tube #5
O.OpM Glyz.
5.0 ~M ELl
sx10 PFU/ml ~6
Tube #9
O.OpM Glyz.
5.0 ~M EL2
sx10 PFU/ml ~6
Tube #13
O.OpM Glyz.
5.0 ~M EL3
sx10 PFU/ml ~6
Tube #6
10pM Glyz.
5.0 ~M ELl
sx10 PFU/ml ~6
Tube #10
10pM Glyz.
5.0 ~M EL2
sxlO PFU/ml ~6
Tube #14
10pM Glyz.
5.0 ~M EL3
sxlO PFU/ml ~6
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Tube #7
100pM Glyz.
'5.0 ~M ELl
sxlO PFU/ml ~6
Tube #11
100pM Glyz.
5.0 ~M EL2
sx10 PFU/ml ~6
Tube #15
lOOpM Glyz.
5.0 ~M EL3
SxlO PFU/ml ~6
Tube #8
lmM Glyz
5.0 ~M ELl
SxlO PFU/ml &lJ6
Tube #12
lmM Glyz
5.0 ~M EL2
Sx10 PFU/ml &lJ6
Tube #16
lmM Glyz
5.0 ~M EL3
Sx10 PFU/ml &lJ6
10ml of 5 X 105 PFU/ml of phage is ready in incubation
tubes. At time t = -1 minute, the respective exogenous
lipid is added to its tUbe and heavily vortexed. Time, t=o,
begins after the respective concentration of glycyrrhizin is
added to the proper tube and vortexed. The time, t=o, is
staggered by 10 minutes along each of 16 incubation tUbes to
allow time for plating. At time, t = 30 minutes, three
dilutions are made from each of 16 incubation tubes. These
three dilutions correspond to plating concentrations of 5 x
102 PFU/ml, 5 x 101 PFU/ml and 5 x 100 PFU/ml of the
original dilution lineage. Two plates are made from each of
the three plating concentrations, hence a total of six
concentration to allow a wider and accurate range of
counting.
plates per incubation tube; two at each plating
plaque
The control for this entire experiment is incubation
tube #1.
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~ Data section
TABLE 12. Summary of the effects of increased
concentrations of glycyrrhizin in the presence
of a protective level of an exogenous lipid.
PLAQUES PER PLATE AND PERCENT INACTIVATION
GLYCYRRHIZIN INCUBATION CONCENTRATIONS
O.O~M 10~M 100~M 1.0mM
Lipid
PFU/ml
Plated
[~6) 1 2 1
PLATES
2 1 2 1 2
CONTROL
5x102
5x101
5x100
Average (nx100 )
% Inactivation
Phosphatidyl
Choline 5x102
5x101
5x100
Average (nx100 )
% Inactivation
680 820 8 4
62 71 0 1
5 9 0 0
7.05 0.055
0.0% 99.25%
640 730 290 220
78 69 2 1
4 7 0 0
6.57 2.03
6.8% 71.2%
o 1
o 0
o 0
0.002
100%
146 186
1 0
o 0
1.44
79.6%
o 1
o 0
o 0
0.001
100%
31 31
o 0
o 0
0.23
96.8%
Arachidylic Acid
5x102
5x101
5x100
Average (nx100 )
% Inactivation
Cholesterol
5x102
5x101
5x100
Average (nx100 )
% Inactivation
750 870
55 62
6 8
6.98
0.9%
850 890
49 77
6 11
7.83
-1.1%
570 530
3 2
o 0
4.01
43.1%
180 120
1 0
o 0
1.33
81.2%
610 400
2 5
o 0
4.27
39.5%
170 190
1 0
o 0
1.54
78.2%
490 460
3 5
o 0
4.37
38.0%
270 240
1 2
o 0
2.03
71.2%
Control plates contained O.OpM of the respective exogenous lipid and O.OpM of glycyrrhizin.
The above data was obtained using the plaque assay at an incubation time of 30 minutesi incubation
temperature of 20°Ci respective incubation concentration of glycyrrhizin of OpM, 10pM, 100pM and,
1mMi a phage 16 incubation concentration of Sx10S PFU/mli and a SpM incubation concentration of each
respective exogenous lipid, except for a O.OpM concentration for the control plate. There were
three plated concentrations of phage 16 namely, Sx102 PFU/ml, Sx101 PFU/ml, and Sx100 PFU/ml with
host HB10Y. Two plates at each concentration were made. A count of plaques per plate was made. An
average was calculated from plaque count data from all plated concentrations and both plates and
normalized to the nx100 PFU/ml plate count.
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~ Graph section
GRAPH 6. Summary of the effects of increased concentrations
of glycyrrhizin in the presence of a protective
level of an exogenous lipid.
EFFECTS OF INCREASED GLYCYRR.HIZIN ON
PROTECTIVE LEVELS OF EXOGENOUS LIPIDS
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Control plates contained O.O~M of the respective exogenous lipid
and O.O~M of glycyrrhizin. Data for the above graph is found in Table
12 and was obtained using the plaque assay at an incubation time of 30
minutes; incubation temperature of 20oC~ respective incubation
concentration of glycyrrhizin of O~M, 10~M, 100~M and, 1mM~ a phage ~6
incubation concentration of SxlO S PFU!ml; and a S~M incubation
concentration of each respective exogenous lipid, except for a O.O~M
concentration for the control plate. There were three plated
concentrations of phage ~6 namely, Sxl02 PFU!ml, SxlO l PFU!ml, and SxlOO
PFU!ml with host HBlOY. Two plates at each concentration were made. A'
count of plaques per plate was made. An average was calculated from
plaque count data from all plated concentrations and both plates. From
calculated averages and control plates a percent inactivation was
calculated.
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~ Results Summary
At 10~M concentration, glycyrrhizin alone inactivates
~6 to practically 100%.
From Graph 6 one can see that over a two order of
magnitude increase of glycyrrhizin, both arachidylic acid
and cholesterol maintained their protective level against
the virucidal activity of glycyrrhizin. In particular, with
10~M concentration of arachidylic acid the percent
inactivation of ~6 by 10~M of glycyrrhizin was reduced
from 100% to an average of about 40% ( +j- 10%). with a
constant 10~M concentration of arachidylic acid and
increasing concentrations of glycyrrhizin through 100~M and
up to 1mM, the percent inactivation was maintained at an
average of 40% ( +j- 10% ). Also, with 10~M concentration
of cholesterol the percent inactivation of ~6 by 10~M of
glycyrrhizin was reduced from 100% to an average of about
75% ( +j- 10%). With a constant 10~M concentration of
cholesterol and increasing concentrations of glycyrrhizin
through 100~M and up to 1mM, the percent inactivation was
maintained at an average of 75% ( +j- 10% ).
Phosphatidyl choline behaved differently. As
glycyrrhizin concentrations increased from 10~M to 1.0mM the
percent inactivation recovered from 70% back near 98% while
the concentration of PC was held constant throughout.
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~ Conclusions and Discussion
One can easily see that the virucidal activity of
glycyrrhizin is sensitive and reduced by certain lipids.
Some of these lipids, to which glycyrrhizin is sensitive,
can maintain their neutralizing ability against a hundred
fold increase in glycyrrhizin. This is an unexpected
result. I had expected that the lipids would alter
virucidal activity and in particular the virucidal activity
of glycyrrhizin. I had also anticipated that lipid effects
would reduce the virucidal activity of glycyrrhizin. I had
~~
also expected that certain lipids would be more effective
and others uneffective.
The results that are unexpected are that for some
lipids, relatively low concentrations are able to reduce the
virucidal activity of glycyrrhizin by 25% to 60%. The
concentration at which this occurs is equal to the
concentration of glycyrrhizin. It is also unexpected that,
although the concentration of the virucidal agent,
glycyrrhizin, is increased some lipids maintain
protective or neutralizing ability.
their
Three speculative models to explain the neutralizing
phenomenon were presented in the previous Discussion section
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of this thesis. The speculative model which more closely
explains these results is not immediatly obvious The
aggregate model seems most plausible simply based upon the
natural occurance of glycyrrhizin found in glycoside
compounds. There may be more dynamics involved among phage,
glycyrrhizin and the protective lipids.
One must at least first, propose, and second, consider,
possibilities even though due consideration may give rise to
evidence that the possibility is not probable or even
reasonable. In considering a possibility with respect to
protective effects of certain lipids, one important thing to
remember is that the virucidal activity of glycyrrhizin is
being reduced by a percentage and not that glycyrrhizin is
rendered completely inactive. At least some molecules are
still quite active and do inactivate phage from at least 40%
to 75%. What is being measured is virucidal activity in
terms of percent inactivation. 'Viral Inactivation' is
being measured. Also, viral inactivation is reduced but not
eliminated. The dynamics of molecules cannot be directly
explained from these inactivation measurements because first
the dynamics of interaction of glycyrrhizin with ~6 surface
molecules must be examined. What is the turn over rate or
dynamics and also the molecular mechanical dynamics of
glycyrrhizin molecules involved in phage inactivation and
with neutralizing-lipids?
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If protective lipids and glycyrrhizin yield a
virucidally inactive change to glycyrrhizin then there are
static factors in virucidal neutralization. If protective
lipids interact dynamically with glycyrrhizin then there is
no inactivation of glycyrrhizin and its potential as a
virucidal compound has a dynamic rate. Likewise, if the
virucidal activity of glycyrrhizin yields a chemically
static change to glycyrrhizin such that after the
participation of a single glycyrrhizin molecule with ~6
surface molecules it becomes virucidally inactive then this
is modeled as a static factor. If one glycyrrhizin molecule
can repeatedly participate in inactivating, in this case,
dislodging phage protein then its potential for inactivating
phage is not only concentration dependent but time dependent
as well. These parameters are directly dependent upon
molecular mechanisms.
The main point being raised, but not concluded, is that
incubation time was also held constant. In a dynamic system
there are turn over rates and time factors are usually
involved. Experiments which examine incubation time as a
variable may indicate that the virucidal activity of
glycyrrhizin at a given temperature and concentration may be
reduced or rather slowed down in the presence of a
protective lipid. This means that to recover the same
88
virucidal inactivation levels before neutralizing lipid is
added simply adding more glycyrrhizin may not be
sufficient. possibly, in the presence of certain protective
molecules, a longer incubation time might yield the recovery
of original inactivation values of a virucidal compound
rather than increased concentration.
A comprehensive formula which identifies and
characterizes all the variables involved in the virucidal
potential or virucidal dynamics of a compound can begin as a
function of several simple variables. Virucidal potential
is a function of these variables despite their complexities.
In order to begin to identify and characterize the
relationship between variables in antiviral research a
theoretical mathematical model can be described. A starting
point in the identification of such a function can be
described by an Inactivation Potential formula (IP).
Inactivation Potential Formula
IP - inactivation potential is expressed as a percent
IP = 100% would be 0 plaques wi control plates
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For simplicity incubation and final concentrations of
neutralizing agents, synergistic agents and potentially
unwanted antiviral agents are not introduced in our initial
early experiments and It, IT are held constant; therefore IP
formula can be simplified as:
What is attempted to be examined first is each
parameter individually while holding all others constant:
IP = f1a(ICv )
IP = f1b(FCv )
IP = f1c(ICa )
IP = f1d(FCa )
After or in determining the effects of this independent
variables alone, the effects of the relationships between
these can be considered:
IRv/a The ratio of virus concentration to
antiviral agent concentration at the time
of incubation.
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There are relationship between certain parameters that
dictate that other parameters in the IP function cannot be
overlooked. For instance, if a final plated concentration
is equal to an incubation concentration that is showing some
effect then the effects of some final plated concentrations
diluted from higher incubation concentrations cannot be
cannot be ignored.
Tube Number
Incubation Concentration
Dilution by 100
Final Plated Concentration
Effect (Yes/No)
1
10,000
+ 100
100
YES
2
1000
100
10
YES
3
100
100
1
YES
4
10
100
0.1
NO
Note that there was an effect noted when incubating at
10,000; at 1000; and at 100. But also observe that the
Incubation Concentration of 100 which has an effect is also
one of the Final Plated Concentrations which observations
are based upon. Hence, if an ICn exist which equals a FCm
then ICn results cannot be simply accepted. In the above
example IC3 = FC1 .
Essentially if there exists an IP > 10% for IPCO(N,x)
and IPCO(x,M) exists. That is if there is a nominal percent
inactivation from a given incubation concentration and
there also exists a final concentration equal to that same
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incubation
inactivation.
concentration showing nominal percent
Also if the effects of a potentially unwanted virucidal
compound affect inactivation percentages greater than (+/-)
1% then ICp cannot be ignored or:
if IP( ICp = X ) - IP( ICp = 0) > 1%
then ICp = X cannot be ignored.
and also with respect to ratios:
and FCV/ p cannot be ignored if (FC/IC) > 0.01),
that is, if the incubation concentration has not been
diluted by a factor of 100 or more.
In addition the formula of the IP function would
include various rates such as the rate at which phage is
inactivated by a virucidal agent. This rate PIR, phage
inactivation rate for example, would be experimentally
determined and its units would be PFU/ml/sec.
PIR phage inactivation rate PFU/ml/second
at STP, no ICn
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An example formula might be:
lP = (PlR x e g(lT,lt) x (lCa/lCv) ) _ e g(lT,lt) x (lCn/lCa)
As an exam [ple the inactivation potential may
exponentially increases by the incubation ratios of
antiviral agent to virus multiplied by an inactivation rate
factor and subtracted (reduced by) by the exponentially
increasing incubation concentration ratio of a neutralizing
agent to antiviral agent. The exponential increase is
mUltiplied by a factor g(), which is a function of
incubation time and temperature.
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In summary, variables that effect virucidal activity of
a potential virucidal compound must be identified,
characterized and measured. From empirical and experimental
data a parameterized formula can be constructed to model
inactivation potential as a function of these variables.
Experiments in this thesis have shown that parameters
of the IP formula do exist and represent variables involved
in determining virucidal activity. This research has also
shown that some variables act upon specific aspects of
virucidal activity and sometimes only under certain
conditions. Each variable can be dependent or independent.
Each variable can be expressed as a value, a constant, be
characterized by a rate or an equation. Most of these
variables at this point would need to be determined
experimentally. The basis of identifying variables,
characterizing virucidal dynamics and formularizing
inactivation potential is to move more closely to a
predictive model.
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Retinoid and PM2 Studies
~ Rationale and Hypothesis
Previous work in this lab had shown that retinoids were
generally effective against lipid containing viruses (1, 4).
At that time all-trans isomers of retinal, retinol and
retinoic acid were studied. In addition some retinoids were
also shown to be effective against protein-coated viruses
such as PM2 and SV40. Retinoic acid (all trans) was the
most active retinoid against PM2, which is protein-coated
and contains an internal lipid bilayer. Retinoids are
amphipathic compounds which have a polar and functional R
group at the end of the hydrocarbon tail. In order to
investigate the effective structural nature of amphipathic
compounds both the conformation of the hydrocarbon tail and
functional groups between conformations were studied for
their virucidal activity against phage PM2.
I had hypothesized that the cis-isomer configurations
would be less effective than their all-trans isomer
equivalents at intercalating into the viral protein coat due
to the isomeric kink in the hydrocarbon tail and therefore
would be less effective at inactivating the virus.
I had also hypothesized that the retinoic acid
functional group would remain the most effective functional
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group, even within the cis-isomer group, at interacting
within the protein-coat and causing viral inactivation.
This evidence would also serve to further elucidate the
potential mechanisms by which the retinoids are interacting
with PM2.
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~ Experimental Design and Method
Concentrations of O.O~M, O.l~M, 1.0~M, 10.0~M, and
100~M of cis and trans isomers of retinoids were tested to
determine their respective percent inactivation curve.
The retinoids studied are retinal, 9-cis-retinal, 13-
cis-retinali all-trans-retinol, 13-cis-retinoli all-trans-
retinoic acid and 13-cis-retinoic acid.
The general plaque assay was followed. Incubation
tubes containing 5 x 105 PFU/ml of phage PM2 were prepared
at a volume of 10ml. The respective concentrations listed
above of each retinoid were added at time t=o and vortexed.
All tubes incubated for 30 minutes. Final
concentrations of 5 x 103 PFU/ml and 5 x 101 PFU/ml
above tubes were made by dilution. O.lml of
plating
of the
phage
concentration samples were added to 10ml top agar tubes
which already contained 0.4ml of bacterial host which was
then vortexed and immediatly plated. Top agar tubes were
cooled to 45°C before either host or phage were added.
Plates sat for 24-36 hours and then plaques were counted.
The concentrations used were all soluble in Q-Medium
(see Appendix A) which was used for host cell growth. The
O.O~M concentration of each retinoid were used as a control
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and to normalize percent inactivation. This has yielded an
inactivation curve for each retinoid on PM2.
In addition experiments were done to test the effects
of each retinoid on normal host lawn growth without any
phage present. This was done to ensure that plaque counts
and host lawn morphology is soley due to phage inactivation
and not from interference by any of the retinoids with
normal host growth.
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~ Data Section
TABLE 13-A. Retinal (all trans) Plaque Counts.
Plaque assay data counting plaques per plate.
PLAQUES PER PLATE - RETINAL (ALL TRANS)
PLATED CONCENTRATION
Retinal 5 x 101 PFU/ml 5 x 100 PFU/ml
all-trans
Incubation EXPERIMENTAL RUN PERCENT
Concentration 1 2 1 2 INACTIVATION
0.0 JJM 47 58 5 6 0%
0.1 JJM 47 48 5 4 9%
1.0 JJM 51 42 4 5 11%
10 JJM 53 49 4 5 3%
100 JJM 42 44 4 4 19%
1.0 roM 30 37 2 4 36%
10 roM 34 35 3 3 34%
The above data was obtained using the plaque assay at
an incubation time of 30 minutes, incubation temperature o~
20°C, and a phage PM2 incubation concentration of 5xlO
PFUjml.
There were two plated concentrations of phage PM2
namely, 5X101 PFUjml and 5xlOO PFUjml with host BAL31. The
experiment was run two times at seven concentrations of the
respective retinoid. A count of plaques per plate were
made. An average of percent inactivation was calculated
from an average of plaque count data from each plated
concentration, and both runs, and a percentage was then
based on O.O~M control at 0% inactivation.
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TABLE 13-B. g-cis Retinal Plaque Counts.
Plaque assay data counting plaques per plate.
PLAQUES PER PLATE - 9-cis RETINAL
PLATED CONCENTRATION
9-cis 5 x 101 PFU/ml 5 x 100 PFU/ml
Retinal
Incubation EXPERIMENTAL RUN PERCENT
Concentration 1 2 1 2 INACTIVATION
0.0 J.JM 55 58 6 6 0%
0.1 J.JM 55 46 5 5 10%
1.0 J.JM 60 41 5 5 10%
10 J.JM 62 49 4 6 2%
100 J.JM 53 46 4 4 6%
1.0 roM 42 39 3 4 28%
10 roM 46 38 3 4 25%
The above data was obtained using the plaque assay at
an incubation time of 30 minutes, incubation temperature o~
20 o C, and a phage PM2 incubation concentration of 5x10
PFU/ml.
There were two plated concentrations of phage PM2
namely, 5X101 PFU/ml and 5X10 0 PFU/ml with host BAL31. The
experiment was run two times at seven concentrations of the
respective retinoid. A count of plaques per plate were
made. An average of percent inactivation was calculated
from an average of plaque count data from each plated
concentration, and both runs, and a percentage was then
based on O.O~M control at 0% inactivation.
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TABLE 13-0. 13-cis Retinal Plaque Counts.
Plaque assay data counting plaques per plate.
PLAQUES PER PLATE - 13-cis RETINAL
PLATED CONCENTRATION
13-cis 5 x 101 PFUjml 5 x 100 PFUjml
Retinal
Incubation EXPERIMENTAL RUN PERCENT
Concentration 1 2 1 2 INACTIVATION
0.0 /-lM 64 66 7 6 0%
0.1 /-lM 65 56 6 5 7%
1.0 /-lM 68 51 6 5 8%
10 /-lM 67 53 6 6 8%
100 /-lM 63 56 6 5 9%
1.0 roM 55 49 5 4 20%
10 roM 56 51 6 4 18%
The above data was obtained using the plaque assay at
an incubation time of 30 minutes, incubation temperature O~
20°C, and a phage PM2 incubation concentration of 5x10
PFU/ml.
There were two· plated concentrations of phage PM2
namely, 5X101 PFU/ml and 5X10 0 PFu/ml with host BAL31. The
experiment was run two times at seven concentrations of the
respective retinoid. A count of plaques per plate were
made. An average of percent inactivation was calculated
from an average of plaque count data from each plated
concentration, and both runs, and a percentage was then
based on O.O~M control at 0% inactivation.
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TABLE 13-D. Retinol (all-trans) Plaque Counts.
Plaque assay data counting plaques per plate.
PLAQUES PER PLATE - RETINOL (ALL-TRANS)
PLATED CONCENTRATION
Retinol 5 x 101 PFU/ml 5 x 100 PFU/ml
all-trans
Incubation EXPERIMENTAL RUN PERCENT
Concentration 1 2 1 2 INACTIVATION
0.0 J.lM 68 79 8 8 0%
0.1 J.lM 69 70 7 7 5%
1.0 J.lM 74 65 7 7 6%
10 J.lM 67 73 6 7 5%
100 J.lM 68 69 5 5 7%
1.0 roM 39 32 4 4 52%
10 roM 24 BP 2 1 65%
The above data was obtained using the plaque assay at
an incubation time of 30 minutes, incubation temperature Os
20°C, and a phage PM2 incubation concentration of 5x10
PFU/ml.
There were two plated concentrations of phage PM2
namely, 5X101 PFU/ml and 5X10 0 PFU/ml with host BAL31. The
experiment was run two times at seven concentrations of the
respective retinoid. A count of plaques per plate were
made. An average of percent inactivation was calculated
from an average of plaque count data from each plated
concentration, and both runs, and a percentage was then
based on O.O~M control at 0% inactivation.
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TABLE 13-E. 13-cis Retinol Plaque Counts.
Plaque assay data counting plaques per plate.
PLAQUES PER PLATE - 13-cis RETINOL
PLATED CONCENTRATION
13-cis 5 x 101 PFU/ml 5 x 100 PFU/ml
Retinol
Incubation EXPERIMENTAL RUN PERCENT
Concentration 1 2 1 2 INACTIVATION
0.0 IJM 57 66 6 8 0%
0.1 IJM 58 67 6 7 0%
1.0 IJM 63 63 7 7 0%
10 IJM 55 58 6 7 8%
100 IJM 49 51 5 5 19%
1.0 roM 33 32 3 4 47%
10 roM 25 21 2 1 56%
The above data was obtained using the plaque assay at
an incubation time of 30.minute~, incu~ation t 7mperature 0t20°C, and a phage PM2 lncubatlon concentratlon of 5x10
PFU/ml.
There were two plated concentrations of phage PM2
namely, 5x101 PFU/ml and 5X10 0 PFU/ml with host BAL31. The
experiment was run two times at seven concentrations of the
respective retinoid. A count of plaques per plate were
made. An average of percent inactivation was calculated
from an average of plaque count data from each plated
concentration, and both runs, and a percentage was then
based on O.O~M control at 0% inactivation.
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TABLE 13-F. Retinoic Acid (all-trans) Plaque Counts.
Plaque assay data counting plaques per plate.
PLAQUES PER PLATE - RETINOIC ACID (ALL-TRANS)
PLATED CONCENTRATION
Retinoic Acid 5 x 103 PFU/ml 5 x 101 PFU/ml
all-trans
Incubation EXPERIMENTAL RUN PERCENT
Concentration 1 2 1 2 INACTIVATION
0.0 pM »> »> 55 61 0%
0.1 pM »> »> 25 31 51%
1. 0 pM »> »> 14 17 73%
10 pM » @180 2 1 97%
100 pM 13 18 0 0 99%
1.0 roM 0 1 0 0 100%
10 roM BP BP BP BP ---
The above data was obtained using the plaque assay at
an incubation time of 30 minutes, incubation temperature 0;
20°C, and a phage PM2 incubation concentration of 5x10
PFU/ml.
There were two plated concentrations of phage PM2
namely, 5x103 PFU/ml and 5x101 PFU/ml with host BAL31. The
experiment was run two times at seven concentrations of the
respective retinoid. A count of plaques per plate were
made. An average of percent inactivation was calculated
from an average of plaque count data from each plated
concentration, and both runs, and a percentaga was then
based on O.O~M control at 0% inactivation.
'{
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TABLE 13-G. 13-cis Retinoic Acid Plaque Counts.
Plaque assay data counting plaques per plate.
PLAQUES PER PLATE - 13-cis RETINOIC ACID
PLATED CONCENTRATION
13-cis 5 x 101 PFU/ml 5 x 100 PFUIml
Retinoic Acid
Incubation EXPERIMENTAL RUN PERCENT
Concentration 1 2 1 2 INACTIVATION
0.0 IJM 50 55 5 6 0%
0.1 IJM 39 46 5 5 19%
1.0 IJM 31 37 4 4 35%
10 IJM 13 20 2 2 68%
100 IJM 13 18 2 2 70%
1.0 roM 6 10 1 1 85%
10 roM 10 BP BP BP ---
The above data was obtained using the plaque assay at
an incubation time of 30 minutes, incubation temperature o~
20°C, and a phage PM2 incubation concentration of 5x10
PFU/ml.
There were two plated concentrations of phage PM2
namely, 5X101 PFU/ml and 5x100 PFU/ml with host BAL31. The
experiment was run two times at seven concentrations of the
respective retinoid. A count of plaques per plate were
made. An average of percent inactivation was calculated
from an average of plaque count data from each plated
concentration, and both runs, and a percentage was then
based on O.O~M control at 0% inactivation.
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~ Graph section
GRAPH 7-A. Percent Inactivation Curve of all Retinoids
Tested upon phage PM2.
Comparative PM21nactivation between
cis and all-trans Retinoid Isomers
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Data for the above graphs were obtained
plaque assay at an incubation time of 30 minutes,
temperature of 20°C, and a phage PM2
concentration of 5xl05 PFUjml.
There were two plated concentrations of phage PM2
namely, 5xl01 PFUjml and 5X100 PFUjml with host BAL31. The
experiment was run two times at seven concentrations of the
respective retinoid. A count of plaques per plate were
made. An average of percent inactivation was calculated
from an average of plaque count data from each plated
concentration, and both runs, and a percentage was then
based on O.O~M control at 0% inactivation.
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GRAPH 7-B. Percent Inactivation Curve of all Retinal
Isomers Tested upon phage PM2.
Comparative PM21nactivation between
cis and all-trans Retinal Isomers
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Data for the above graphs were obtained
plaque assay at an incubation time of 30 minutes,
temperature of 20°C, and a phage PM2
concentration of 5X105 PFU/ml.
There were two plated concentrations of phage PM2
namely, 5X101 PFU/ml and 5X10 0 PFU/ml with host BAL31. The
experiment was run two times at seven concentrations of the
respective retinoid. A count of plaques per plate were
made. An average of percent inactivation was calculated
from an average of plaque count data from each plated
concentration, and both runs, and a percentage was then
based on O.O~M control at 0% inactivation.
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GRAPH 7-C. Percent Inactivation Curve of all Retinol
Isomers Tested upon phage PM2.
Comparative PM21nactivation between
cis and all-trans Retinol Isomers
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Data for the above graphs were obtained
plaque assay at an incubation time of 30 minutes,
temperature of 20°C, and a phage PM2
concentration of 5xl05 PFUjrnl.
There were two plated concentrations of phage PM2
namely, 5Xl01 PFUjml and 5Xl00 PFUjml with host BAL31. The
experiment was run two times at seven concentrations of the
respective retinoid. A count of plaques per plate were
made. An average of percent inactivation was calculated
from an average of plaque count data from each plated
concentration, and both runs, and a percentage was then
based on O.O~M control at 0% inactivation.
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GRAPH 7-D. Percent Inactivation Curve of all Retinoic Acid
Isomers Tested upon phage PM2.
comparative PM2 Inactivation between
cis and all-trans Retlnoic Acid Isomers
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Data for the above graphs were obtained
plaque assay at an incubation time of 30 minutes,
temperature of 20°C, and a phage PM2
concentration of 5x105 PFU/ml.
There were two plated concentrations of phage PM2
namely, 5x101 PFU/ml and 5x10 0 PFU/ml with host BAL31. The
experiment was run two times at seven concentrations of the
respective retinoid. A count of plaques per plate were
made. An average of percent inactivation was calculated
from an average of plaque count data from each plated
concentration, and both runs, and a percentage was then
based on O.O~M control at 0% inactivation.
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~ Results Summary
Retinoic acid (all-trans) is the most active virucidal
agent of the retinoids tested against phage PM2. The 13-cis
isomer of retinoic acid is the second most virucidal agent
and is more active than all other isomers of retinal and
retinol.
Table 14. Comparison of Percent Inactivation among
all the Retinoids Tested upon phage PM2.
RETINOID PERCENT INACTIVATION COMPARISON
Retinoid Isomer
Retinoic Acid (all-trans)
13-cis Retinoic Acid
Retinal (all-trans)
13-cis Retinol
13-cis Retinal
Retinol (all-trans)
9-cis Retinal
Percent Inactivation
99%
70%
19%
19%
9%
7%
6%
Data for this table is taken from the 100~M
concentration of each retinoid isomer tested in Tables 13-A
to 13-G. Table 14 is listed in descending order of percent
inactivation.
By examining Graph 7-B, 7-C and 7-D one can see that
overall the all-trans isomer of each retinoid demostrated
greater virucidal activity than its respective cis-isomers.
A general ranking among the three retinoid groups
tested is ( 1st ) Retinoic Acid, ( 2nd ) Retinol, and ( 3rd
Retinal. Slight variations in ranking at certain data
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points within the inactivation curves may exist but overall
averages yield the above general ranking.
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~ Conclusion and Discussion
Previous work in this lab has shown that retinoids,
especially retinoic acid, showed a substantial virucidal
activity against the phage PM2. These retinoids have
also been shown to be effective against other protein
coated viruses such as SV40 (1, 4). In this section of this
thesis research the virucidal activity of the cis-isomer
configurations were studied and compared to their
corresponding all-trans isomer results. Retinoids are
amphipathic compounds which have a functional R group at the
end of its polar tail. Comparing results of virucidal
activity between retinoid functional groups as well as
changes in isomeric conformations indicate that the acid
group COOH and the all-trans isomers are the more effective
components of the retinoid compounds tested against the
protein-coated phage PM2. This suggests that these
components may be, in general, more effective against other
protein coated viruses as well.
It was hypothesized that the cis-isomer configurations
would be less effective than their all-trans isomer
equivalents. This is not the case for the retinal and
retinol isomers. The cis-isomers of retinal and retinol did
not show a greater nor a substantially less effective
virucidal activity compared to their all-trans isomers. The
112
13-cis retinoic acid did however, show an appreciable
reduction in percent inactivation than the all-trans isomer
of retinoic acid. The explaination for this reduced
activity is most likely due to the decreased ability of the
13-cis isomer of retinoic acid at intercalating into the
viral-protein-coat due to the isomeric kink in the
hydrocarbon tail. The cis-isomer kink may cause a
resistance or require additional energies in order to
intercalate into the protein coat. In addition the cis-
isomeric kink may distort the ability of the functional
polar group to interact with either the protein outer coat
or, after intercalation, the interaction with the inner
lipid membrane. As previously stated other researchers
believe that the retinoids are interacting with protein,
specifically the protein composing the outer-coat of the
virion.
I had also hypothesized and shown, in this research,
that the retinoic acid functional group is the most
effective functional group. This research supports previous
work by showing that all-trans retinoic acid was the most
active retinoid against the protein-coated phage PM2. other
researchers and myself speculate that the interaction of the
retinoid polar tails within the protein-coat lead to viral
inactivation. A proposed mechanism by which the retinoids
are interacting with phage PM2 and lead to virion disruption
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may begin with intercalation into the protein coat then
followed by possible penetration and interaction with the
internal lipid bilayer of the phage PM2.
Retinoic acid isomers were the most active against
phage PM2 but the least active against phage ~6. Retinol
and retinal where the least active against phage PM2 but the
most active against phage ~6. The outer structure of phage
PM2 is protein, whereas the outer structure of phage ~6 is
lipid. Glycyrrhizin was more effective against phage ~6
than phage PM2. Both phage ~6 and herpes virus possess
external lipid-enveloped structures and were comparatively
more susceptible to both retinol and glycyrrhizin. Phage
PM2, with its exterior protein coat, was comparatively less
susceptible to both retinol and glycyrrhizin. The eOOH R-
group of retinoic acid is the most effective retinoid tested
upon the protein-coated phage PM2 and, although untested,
speculatively the cis-isomer would also be effective upon
SV40 virus as well. I propose as a possible explanation
that the protein of the outer protein-coat may require the
activity and exposure of the eOOH R group in order to be
more affected by polar group~ of retinoids and cause protein
coat disruption.
Although glycyrrhizin was less effective on PM2 than
~6, it did show virucidal activity. The amphipathic nature
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of glycyrrhizin does include a eOOH group, as well as the
-OH group. This supports the speculative conclusion
concerning the effectiveness of the acid eOOH group on PM2.
The molecular availableness or exposure of the eOOH group
most likely has some contribution to the effectiveness of
glycyrrhizin. This can be further sUbstatiated since the
cis-isomer of retinoic acid shows a reduced activity
(reduced exposure due to kink) and that glycyrrhizin shows a
respectable activity against PM2 due to the eOOH group
although less susceptability than ~6 due to a greater
sensitivity of ~6 to the -OH group.
The hypothesis of this research has been investigated
and verified and has provided some evidence to further
suggest the nature of retinoid inactivation mechanisms upon
phage PM2. In addition, both objectives of (1.) determining
how the virucidal activity of the cis-isomers of the
retinoids compare with all-trans isomer results on phage PM2
and (2.) which functional group shows greater and consistent
virucidal activity upon the protein-coated phage PM2, have
been completed.
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APPENDIX A
MEDIUM PREPERATION
Q Medium is used for Ba131,
Alteromonas Espejiana, Host forPM2 phage
V Medium is used for HB10Y,
Phaseolicola, Host for t 6 phage
Liquid Medium Ingredients per 1 Liter distilled water.
Component Q Medium V Medium
--------- -------- --------
Tryptone 109 109
Yeast Extract Sg Sg
NaCI 26g 7g
KCI 0.7g l.Sg
MgSO 12g O.Sg
CaCI l.Sg 0
Bottom Agar for Plates.
Use above Liquid Medium ingredients plus 2.0% Agar.
Agar 20g 20g
Top Agar
Use above Liquid Medium ingredients plus 1/2% Agar.
Agar Sg Sg
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APPENDIX ~
GENERAL VIRUCIDAL TEST PROCEDURE
EFFECT OF VARIOUS CONCENTRATIONS OF A COMPOUND
ON A PHAGE-HOST SYSTEM
Materials:
20 sterile tubes
4 bottom agar plates
4 top agar tubes (7-10ml) each
liquid medium
retinoid componds
8 sterile 1ml pipets
Protocol:
Preparation Step
*
Put Top Agar in Large Beaker of Boiling water and
thoroughly melt Top Agar Medium. (PS1.01)
Four sterile tubes should be placed in temperature
bath and allowed to be pre-heated. (PS1.03)
After step (S6.0X) dispense 7-10ml into each
of 4 sterile tubes and place in temperature
bath at (50 C). (PS2.02)
(PS3.00)
add to 9ml of medium
* Host
a.
b.
c.
Bacteria Preparation
Take 1ml of stock bacteria and
into a sterile capped flask.
Flame flask lip and recap.
Put incubation flask on shaker for 1-2 hrs.
It may require up to 10 - 18 hrs depending upon
how long bacterial stock has been in refrige.
Double above 1-2hr time for each week in refrige.
1. Take O.lml of phage stock and then add into
10 ml of medium in a tube. Vortex. When ever vortexing
pinch finger and thumb above liquid level and below
sterile cap to create a vortex node so liquid will
not spin above pinched point. Return stock to
refrigerator. (Sl.01)
2. Take O.lml of above dilution (Sl.01) and then add
into 40ml of medium into a tube. Vortex. (S2.01)
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3.
4.
Dispense 10ml of (52.01) dilution into each of 4
sterile tubes.
The PFU/ml in each of the 4 tubes is about
1.2E10 / ( 100x * 400x) = 3 x 105 PFU/ml
Label the 4 tubes from (53.01) with each
concentration, for example if using ethenol:
0%, 0.4%, 1.0%, 0.4%
(53.01)
respective
(54.01)
5. At a time t=O we will add different concentrations of the
compound to each of the 4 tubes and let them sit
for t=15 minutes at which time we will dilute
the 4 tubes containing phage and plate.
6. Using the ethenol concentrations as an example:
At t=O add O.OOml of compound to the 0.0% tube (56.01)
0.04ml of compound to the 0.4% tube (56.02)
0.10ml of compound to the 1.0% tube (56.03)
0.40ml of compound to the 4.0% tube (56.04)
At this point the tubes contain medium, 3 x 105 PFU/ml
phage, and various (for example 0% to 4%) concentrations of
the compound.
7. At t=15 minutes dilute O.lml from each of 4 (56.0X)
tube into 4 respective tubes containing 10ml medium. (57.01)
This is another dilution of 100. ( 10 / 0.1)
The PFU/ml of these 4 new tubes is 3 x 103 PFU/ml.
8. Retrieve the 4 top agar tube from the temperature bath
that were prepared in step (P51.02).
Add 0.4ml of host bacteria to each of the four
top agar tubes.
Add to the (in)side of the tube and allow to run
down into the agar.
Do not vortex. (58.01)
9. Have pipets already sitting in each of the phage
dilution tubes. Take O.lml from the (57.01) tubes
and pipet down into the 7-10ml top agar tubes for
each (57.01) tube. Immediately vortex for 2 sec.
seconds and Quickly Plate. (59.01)
This is another dilution of 100. 110 / 0.1)
The final concentration is 3 x 10 PFU/ml. This means
about 30 plaques for the 0.0% compound control.
10. Incubate plaques overnight.
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(510.01)
11. Calculate percent survival for each compound
concentrations as follows:
% survival = surviving PFU/ml in [compound)
contol 0.0% PFU/ml
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HSV-1
VZV
NDV
HIV
HBV
APPENDIX Q
VIRUS ABBREVIATIONS
herpes simplex 1 virus
varicella-zoster virus
Newcastle disease virus
human immunodeficiancy virus
hepatitis B virus
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APPENDIX .Q
STANDARD ANTIVIRAL RESEARCH RELATED ABBREVIATIONS
AV
AVA
AVC
AVF
pfu
hpi
IC50ID50LD50LD99MIC
PRP
T~D50
Vlrlon
antiviral
antiviral activity
antiviral compound
antiviral factor
plaque forming units
hours post infection
infectious concentration 50%
infectious dose 50%
lethal dose 50%
lethal dose 99%
minimum inhibitory concentration
pathogenesis related protein
tissue culture dose 50%
virus particle
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